var title_f34_19_35120="Spinal curve osteoporosis";
var content_f34_19_35120=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Progressive spinal curvature in osteoporosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Successive compression or crush fractures, in which there is a collapse of affected bone, may lead to increased curvature of the spine (thoracic kyphosis). As a result, there is typically an abnormal rounding of the upper back, known as \"dowager's hump,\" and loss of height. Due to vertebral fractures and associated height loss, the abdomen may be compressed, causing it to bulge forward. Such patients may note that their abdomens appear larger than before, their clothes no longer fit, and their waist seems to have \"disappeared\" even though they have not gained weight.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35120=[""].join("\n");
var outline_f34_19_35120=null;
var title_f34_19_35121="Angioedema lip 2";
var content_f34_19_35121=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F57090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F57090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Angioedema of the lips",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35121=[""].join("\n");
var outline_f34_19_35121=null;
var title_f34_19_35122="Frykman IV radius fracture AP view";
var content_f34_19_35122=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66573%7EEM%2F79669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66573%7EEM%2F79669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frykman IV radius fracture AP view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This fracture occurred in a 73-year-old osteoporotic woman following a low-energy fall onto her outstretched right hand. Due to the extension of the fracture into the radiocarpal joint and the distal ulnar injury (white arrow), this fracture is categorized as a Frykman IV. Most notable on this image is the displacement of the distal radial fragment (red arrow) and the loss of radial height. Other injuries are present, most notably a scaphoid fracture (black arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Erik L Schroeder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frykman IV radius fracture lateral view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lateral x-ray of the same injury demonstrates significant dorsal displacement and angulation of the distal radial fragment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Erik L Schroeder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35122=[""].join("\n");
var outline_f34_19_35122=null;
var title_f34_19_35123="Gatifloxacin: Pediatric drug information";
var content_f34_19_35123=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gatifloxacin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?4/46/4836?source=see_link\">",
"    see \"Gatifloxacin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/31/44531?source=see_link\">",
"    see \"Gatifloxacin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zymaxid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zymar&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1016073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Quinolone",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1016111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/46/4836?source=see_link\">",
"      see \"Gatifloxacin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;1 year and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zymar&reg;: Days 1 and 2: Instill 1 drop into affected eye(s) every 2 hours while awake (maximum: 8 times/day). Days 3-7: Instill 1 drop into affected eye(s) up to 4 times/day while awake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zymaxid&trade;: Day 1: Instill 1 drop into affected eye(s) every 2 hours while awake (maximum: 8 times/day). Days 2-7: Instill 1 drop into affected eye(s) 2-4 times/day while awake.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zymaxid&trade;: 0.5% (2.5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1016118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     For topical ophthalmic use only; avoid touching tip of applicator to eye, fingers, or other surfaces. Apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1016099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, alfentanil, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, aztreonam, bretylium, buprenorphine, butorphanol, calcium chloride, calcium gluconate, carboplatin, cefazolin, cefotetan, ceftazidime, ceftizoxime, ceftriaxone, chlorpromazine  , cimetidine, cisatracurium, cisplatin, clindamycin, cyclophosphamide, cyclosporine, cytarabine, dexamethasone sodium phosphate,  digoxin, diphenhydramine, dobutamine, dopamine, doxorubicin, droperidol, enalaprilat, esmolol, etoposide, famotidine, fentanyl, fluconazole, fluorouracil, ganciclovir, gemcitabine, gentamicin, granisetron, haloperidol, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, ifosfamide, imipenem/cilastatin, labetalol, leucovorin, lidocaine, lorazepam, magnesium sulfate, mannitol, meperidine, mesna, methotrexate, methylprednisolone sodium succinate, metoclopramide, metronidazole, midazolam, mitoxantrone, morphine, nalbuphine, naloxone, nicardipine, nitroglycerin, ondansetron, paclitaxel, pentamidine, pentobarbital, phenobarbital, potassium chloride, prochlorperazine edisylate, promethazine, propranolol, ranitidine, remifentanil, sodium bicarbonate, sodium phosphates, sufentanil, theophylline, ticarcillin, ticarcillin/clavulanate potassium, tobramycin, trimethoprim/sulfamethoxazole, vecuronium, verapamil, vinblastine, vincristine, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, amphotericin B cholesteryl sulfate complex, cefoperazone, cefoxitin, diazepam, furosemide, heparin, phenytoin, piperacillin, piperacillin/tazobactam, potassium phosphates, vancomycin",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1016095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Store between 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); do not freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1016074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of bacterial conjunctivitis caused by susceptible organisms (FDA approved in ages &ge;1 year and adults).",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F177159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, erythema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Taste disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctival irritation, discharge, dry eye, edema, irritation, keratitis, lacrimation increased, pain, papillary conjunctivitis, visual acuity decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Rhinorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Angioedema, blepharitis (allergic), chemosis, conjunctival cyst, conjunctival hemorrhage, corneal deposits, corneal disorder, corneal ulcer, dermatitis, dizziness, endophthalmitis, eye redness, iritis, keratoconjunctivitis, macular edema, nausea, paresthesia (oral), photophobia, pruritus, subepithelial opacities, tinnitus, tremor, urticaria, uveitis, vision blurred, throat sore",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1016080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gatifloxacin, other quinolone antibiotics, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13243778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in fungal or bacterial superinfection. Contact lenses should not be worn during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1016081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Severe hypersensitivity reactions, including anaphylaxis, have occurred with systemic quinolone therapy, including gatifloxacin. The spectrum of these reactions can vary widely. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.",
"     <b>",
"      Not for injection into the eye.",
"     </b>",
"     Eye drops should not be introduced directly into the anterior chamber of the eye.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F177096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F177108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gatifloxacin has been shown to be fetotoxic in animal studies. Quinolone exposure during human pregnancy has been reported with other agents (refer to Ciprofloxacin (Systemic), Ofloxacin (Systemic), and Norfloxacin monographs). Following ophthalmic administration, serum concentrations of gatifloxacin are below the limits of quantification (&lt;5 ng/mL). Systemic absorption would be required in order for gatifloxacin to cross the placenta.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1016121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs of infection",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1016100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gatifloxacin is an inhibitor of DNA gyrase and topoisomerase IV. DNA gyrase (topoisomerase II) is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair, recombination, and transposition; inhibition is bactericidal.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1016102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Absorption: Not measurable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1016125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/31/44531?source=see_link\">",
"      see \"Gatifloxacin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wash hands before instilling solution. Sit or lie down to instill. Do not touch tip of applicator or let tip of applicator touch eye. Apply light pressure to the inside corner of the eye (near the nose) after each drop. Do not wear contact lenses during therapy. Temporary stinging, blurred vision, or dry eyes may occur. Report persistent pain, burning, excessive tearing, decreased visual acuity, swelling, itching, or worsening of condition. If you experience signs of allergic reaction (eg, itching, rash, respiratory difficulty, facial edema, difficulty swallowing), discontinue use immediately and report to prescriber.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F13243779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evidence of damage to weight-bearing joints in pediatric populations with ophthalmic administration has not been shown.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cervantes LJ and Mah FS, \"Clinical Use of Gatifloxacin Ophthalmic Solution for Treatment of Bacterial Conjunctivitis,\"",
"      <i>",
"       Clin Ophthalmol",
"      </i>",
"      , 2011, 5:495-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/19/35123/abstract-text/21573098/pubmed\" id=\"21573098\" target=\"_blank\">",
"        21573098",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16770 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-D9A34E86B4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35123=[""].join("\n");
var outline_f34_19_35123=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177127\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177128\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016073\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016111\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177100\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177085\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016118\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016099\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016095\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016074\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177159\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016080\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13243778\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016081\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299391\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220595\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177096\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177108\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016121\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016100\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016102\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1016125\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13243779\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16770\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16770|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/46/4836?source=related_link\">",
"      Gatifloxacin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/31/44531?source=related_link\">",
"      Gatifloxacin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_19_35124="Aortic coarctation children PI";
var content_f34_19_35124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Aortic coarctation in a child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 633px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The aorta is the main artery that delivers blood from the heart to the body. Aortic coarctation is a heart defect that causes the aorta to narrow (see arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35124=[""].join("\n");
var outline_f34_19_35124=null;
var title_f34_19_35125="Lacosamide: Drug information";
var content_f34_19_35125=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lacosamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/0/29701?source=see_link\">",
"    see \"Lacosamide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/62/33765?source=see_link\">",
"    see \"Lacosamide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6786825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vimpat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11508103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vimpat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6790311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6790646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Partial onset seizure:",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Initial: 50 mg twice daily; may be increased at weekly intervals by 100 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maintenance dose: 200-400 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     When switching from oral to I.V. formulations, the total daily dose and frequency should be the same; I.V. therapy should only be used temporarily.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6790645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/62/33765?source=see_link\">",
"      see \"Lacosamide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adolescents &ge;17 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6790647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6790648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution when titrating dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild-to-moderate renal impairment: No dose adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute): Maximum dose: 300 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis: Removed by hemodialysis; after 4-hour HD treatment, a supplemental dose of up to 50% should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6790649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution when titrating dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate hepatic impairment: Maximum dose: 300 mg daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe hepatic impairment: Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6790656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vimpat&reg;: 10 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vimpat&reg;: 10 mg/mL (465 mL) [contains phenylalanine 0.32 mg/20 mL, propylene glycol; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vimpat&reg;: 50 mg, 100 mg, 150 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6790309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F9590984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-V",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089816.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089816.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6790652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Administer over 30-60 minutes. Twice daily I.V. infusions have been used for up to 5 days. Can be administered without further dilution or may be mixed with compatible diluents (NS, LR, D",
"     <sub>",
"      5",
"     </sub>",
"     W).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution, tablets: May be administered with or without food. Oral solution should be administered with a calibrated measuring device (not a household teaspoon or tablespoon).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F6790528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, LR, D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6790313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy in the treatment of partial-onset seizures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6790305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lacosamide may be confused with zonisamide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Vimpat&reg; may be confused with Vimovo&trade;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6790443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (31%), headache (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Diplopia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Syncope (adults 1%; dose-related: &gt;400 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (9%), ataxia (8%), somnolence (7%), coordination impaired (4%), vertigo (4%), depression (2%), memory impairment (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Vomiting (9%), diarrhea (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Contusion (3%), skin laceration (3%), injection site pain/discomfort (3%), irritation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Tremor (7%), gait instability (2%), weakness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (8%), nystagmus (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anemia, atrial fibrillation/flutter, atrioventricular block, bradycardia, cerebellar syndrome, cognitive dysfunction, drug reaction with eosinophilia and systemic symptoms (DRESS), dysarthria, euphoria-like subjective responses, falling, hallucination, hepatitis, multiorgan hypersensitivity, nephritis, neutropenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6790319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6790403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Lacosamide may prolong PR interval; second degree or higher AV block has also been reported. Use caution in patients with conduction problems (eg, first/second degree atrioventricular block and sick sinus syndrome without pacemaker), myocardial ischemia, heart failure, or if concurrent use with other drugs that prolong the PR interval; ECG is recommended prior to initiating therapy and when at steady state. Instruct patients to contact their healthcare provider if signs or symptoms of conduction problems occur (eg, low or irregular pulse, feeling of lightheadedness and fainting). During investigational trials, atrial fibrillation/flutter, or syncope occurred slightly more often in patients with diabetic neuropathy and/or cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Dizziness and ataxia may occur during therapy; patients should be cautioned about performing tasks which require alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiorgan hypersensitivity reactions (drug reaction with eosinophilia and systemic symptoms [DRESS]): Potentially serious (sometimes fatal, possibly delayed) multiorgan hypersensitivity reactions have been reported with some antiepileptic drugs (rare); monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, and/or hematologic organ systems; gradual discontinuation and conversion to alternate therapy may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Not recommended for use in patients with severe hepatic impairment; dose limitation for mild-to-moderate hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use caution in patients with renal impairment; dose limitation and supplementation for severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute) and hemodialysis, respectively.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually (&ge;1 week) to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6802892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Lacosamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Lacosamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Lacosamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Lacosamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6790523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6790314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6790315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Available information related to use in pregnancy is limited; if inadvertent exposure occurs during pregnancy, close monitoring of the mother and fetus/newborn is recommended (Hoeltzenbein, 2011). Two registries are available for women exposed to lacosamide during pregnancy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pregnant women may contact the North American Antiepileptic Drug (AED) Pregnancy Registry (888-233-2334 or file://www.aedpregnancyregistry.org)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     The healthcare provider or patient may contact the UCB AED Pregnancy Registry (888-537-7734)",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6790317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6790318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is unknown if lacosamide is excreted in human milk. The manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6790651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral solution and tablets may be taken with or without food. Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Vimpat Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/20 mL (20 mL): $50.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Vimpat Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (465 mL): $479.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vimpat Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (60): $370.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (60): $579.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $614.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $614.18",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6790654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with conduction problems or severe cardiac disease should have ECG tracing prior to start of therapy and when at steady-state; suicidality (eg, suicidal thoughts, depression, behavioral changes)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Lacasa (IN);",
"     </li>",
"     <li>",
"      Lacosam (IN);",
"     </li>",
"     <li>",
"      Lacoset (IN);",
"     </li>",
"     <li>",
"      Vimpat (AR, AU, BE, CH, CO, CZ, DE, DK, EE, FR, GB, GR, IE, KP, NL, NO, NZ, PL, PT, RU, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6790564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      In vitro",
"     </i>",
"     studies have shown that lacosamide stabilizes hyperexcitable neuronal membranes and inhibits repetitive neuronal firing by enhancing the slow inactivation of sodium channels (with no effects on fast inactivation of sodium channels).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6790566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral: Completely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~0.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &lt;15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; forms metabolite, O-desmethyl-lacosamide (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Oral: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (95%; 40% as unchanged drug, 30% as inactive metabolite, 20% as uncharacterized metabolite); feces (&lt;0.5%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ben-Menachem E, Biton V, Jatuzis D, et al, &ldquo;Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults With Partial-Onset Seizures,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2007, 48(7):1308-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/19/35125/abstract-text/17635557/pubmed\" id=\"17635557\" target=\"_blank\">",
"        17635557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beyreuther BK, Freitag J, Heers C, et al, &ldquo;Lacosamide: A Review of Preclinical Properties,&rdquo;",
"      <i>",
"       CNS Drug Rev",
"      </i>",
"      , 2007, 13(1):21-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/19/35125/abstract-text/17461888/pubmed\" id=\"17461888\" target=\"_blank\">",
"        17461888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biton V, Rosenfeld WE, Whitesides J, et al, &ldquo;Intravenous Lacosamide as Replacement for Oral Lacosamide in Patients With Partial-Onset Seizures,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2008, 49(3):418-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/19/35125/abstract-text/17888078/pubmed\" id=\"17888078\" target=\"_blank\">",
"        17888078",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doty P, Rudd GD, Stoehr T, et al, &ldquo;Lacosamide,&rdquo;",
"      <i>",
"       Neurotherapeutics",
"      </i>",
"      , 2007, 4(1):145-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/19/35125/abstract-text/17199030/pubmed\" id=\"17199030\" target=\"_blank\">",
"        17199030",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoeltzenbein M, Supcun-Ritzler S, Langthaler M, et al \"Lacosamide During pregnancy: Experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy,\"",
"      <i>",
"       Reprod Toxicol",
"      </i>",
"      , 2011, 31(2):259.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10268 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-FD0A04FE88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35125=[""].join("\n");
var outline_f34_19_35125=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6786825\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11508103\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790311\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790646\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790645\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790647\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790648\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790649\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790656\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790309\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9590984\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874836\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790652\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790528\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790313\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790305\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790443\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790319\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790403\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299564\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6802892\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790523\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790314\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790315\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790317\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790318\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790651\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321857\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790654\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961941\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790564\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6790566\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10268\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10268|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/0/29701?source=related_link\">",
"      Lacosamide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/62/33765?source=related_link\">",
"      Lacosamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_19_35126="Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma";
var content_f34_19_35126=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/19/35126/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/19/35126/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/19/35126/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/19/35126/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/19/35126/contributors\">",
"     Timothy M Kuzel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/19/35126/contributors\">",
"     John A Zic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/19/35126/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/19/35126/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/19/35126/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral T-cell lymphomas (PTCL) are a heterogeneous group of generally aggressive neoplasms that constitute less than 15 percent of all non-Hodgkin lymphomas in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among these, in decreasing frequency of occurrence, are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral T-cell lymphoma, not otherwise specified",
"     </li>",
"     <li>",
"      Anaplastic large cell lymphoma, primary systemic type",
"     </li>",
"     <li>",
"      Angioimmunoblastic T-cell lymphoma",
"     </li>",
"     <li>",
"      Extranodal",
"      <span class=\"nowrap\">",
"       NK/T-cell",
"      </span>",
"      lymphoma, nasal type",
"     </li>",
"     <li>",
"      Subcutaneous panniculitis-like T-cell lymphoma",
"     </li>",
"     <li>",
"      Enteropathy associated T-cell lymphoma",
"     </li>",
"     <li>",
"      Hepatosplenic T-cell lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a PTCL derived from a mature cytotoxic T-cell that commonly mimics panniculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients present with subcutaneous nodules or plaques that, on pathologic evaluation, demonstrate cellular infiltrates in the subcutaneous fat, generally with sparing of the overlying epidermis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17112?source=see_link\">",
"     \"Panniculitis: Recognition and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since its original description, the definition of SPTCL has undergone revisions. The diagnosis of SPTCL is now restricted to primary cutaneous T cell lymphomas expressing",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    T cell receptors (TCRs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/2\">",
"     2",
"    </a>",
"    ]. SPTCL appears to have a much better prognosis than histologically similar tumors expressing",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    TCRs, which are now classified as cutaneous",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T cell lymphomas.",
"   </p>",
"   <p>",
"    The clinical presentation, pathologic features, and diagnosis of SPTCL will be reviewed here. The diagnosis of other subtypes of PTCL and the treatment of the PTCLs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33065?source=see_link\">",
"     \"Initial treatment of peripheral T cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27785?source=see_link\">",
"     \"Treatment of relapsed or refractory peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;SPTCL is an uncommon peripheral T-cell lymphoma accounting for less than 1 percent of all non-Hodgkin lymphoma subtypes. The exact incidence and variation in incidence with geography have not been well characterized.",
"   </p>",
"   <p>",
"    Patients present at a median age of 36 years (range 9 to 79 years) with approximately 20 percent of patients presenting under the age of 20 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/3\">",
"     3",
"    </a>",
"    ]. There appears to be a female predominance with a male:female ratio of 0.5. Up to 20 percent of patients have at presentation an associated autoimmune disease such as systemic lupus erythematosus, juvenile idiopathic arthritis, Sj&ouml;gren's syndrome, or type 1 diabetes mellitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SPTCL typically present with one or more usually painless subcutaneous nodules or poorly circumscribed indurated plaques involving the legs (71 percent), arms (62 percent), trunk (56 percent),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    face (25 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Nodule diameter can vary from 0.5 cm to more than 20 cm. Necrosis may be present, but ulceration is uncommon (6 percent). Single lesions are rare and approximately 80 percent of patients have multiple nodules",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plaques.",
"   </p>",
"   <p>",
"    The lesions may have been previously misdiagnosed as panniculitis or other cutaneous diseases, resulting in one series in a median time from lesion development to diagnosis of seven months (range one month to 10 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/3\">",
"     3",
"    </a>",
"    ]. It is not uncommon for these nodules to initially demonstrate a waxing and waning course and the development of new nodules at different sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/5\">",
"     5",
"    </a>",
"    ]. Given this course, nodules may be seen in various stages of growth and healing, resulting in the presence of lipoatrophy in previously involved areas that have since regressed.",
"   </p>",
"   <p>",
"    It is extremely unusual for patients with SPTCL to have evidence of lymphoma outside of the subcutaneous tissue. Systemic B symptoms (fevers, night sweats, and weight loss) and bone marrow abnormalities are reported in approximately 60 and 20 to 30 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/3\">",
"     3",
"    </a>",
"    ]. Bone marrow involvement by lymphoma is highly unusual; the most common bone marrow abnormality is hemophagocytosis.",
"   </p>",
"   <p>",
"    In a series of 83 patients that used the current definition of SPTCL, 14 (17 percent) had secondary hemophagocytic lymphohistiocytosis (HLH, also called the hemophagocytic syndrome) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/3\">",
"     3",
"    </a>",
"    ]. HLH is an often fatal complication, which may present with high fevers, maculopapular rash, failure to thrive, central nervous system symptoms, hepatosplenomegaly, lymphadenopathy, cytopenias, coagulopathy, abnormal liver function tests, or an extremely high serum ferritin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 45 percent of patients with SPTCL have laboratory abnormalities, the most common of which are anemia, leukopenia, thrombocytopenia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated liver function tests. Radiologic abnormalities on computed tomography (eg, lymphadenopathy, hepatomegaly, pleural effusions) are seen in less than 10 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsy demonstrates a subcutaneous infiltrate of atypical lymphocytes involving the fat lobules, but typically sparing the septae, overlying dermis, and epidermis (",
"    <a class=\"graphic graphic_picture graphicRef82054 \" href=\"mobipreview.htm?6/28/6598\">",
"     picture 1",
"    </a>",
"    ). The neoplastic cells often surround, or rim, the individual fat cells and may invade the deeper dermis, surrounding the sweat glands",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hair follicles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. Fat necrosis and karyorrhexis are common. Vascular invasion is seen in some cases.",
"   </p>",
"   <p>",
"    The neoplastic infiltrate may be comprised of small, medium, or large atypical cells. While there is heterogeneity in cell size among patients, cell size is usually relatively uniform in a given patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/2\">",
"     2",
"    </a>",
"    ]. The nuclei are irregular and hyperchromatic with a rim of pale cytoplasm. Reactive lymphocytes and histiocytes with vacuoles, phagocytized nuclear debris",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ingested lipid are numerous, the latter due to extravasation of lipid from necrotic adipocytes. Other inflammatory cells, such as plasma cells, neutrophils, and eosinophils are generally absent. Non-necrotizing granulomas with multinucleated giant cells may be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;SPTCL tumors typically have the following immunophenotypic features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They express CD3, CD8, and the",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      T-cell receptor (TCR), but are negative for CD4 and CD56.",
"     </li>",
"     <li>",
"      There is strong expression of the cytotoxic granule proteins granzyme B, T-cell intracellular antigen (TIA)-1, and perforin (",
"      <a class=\"graphic graphic_picture graphicRef82054 \" href=\"mobipreview.htm?6/28/6598\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Expression of CD2, CD5,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CD7 is lost in 10, 50, and 44 percent of cases, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Staining is positive for TCR beta and negative for TCR gamma.",
"     </li>",
"     <li>",
"      Scattered, benign CD20 expressing cells may be identified in the background [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clonal T-cell receptor rearrangements are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. In situ hybridization for Epstein-Barr encoded RNA (EBER) is negative. Specific cytogenetic abnormalities have not been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of SPTCL is made with a deep skin biopsy that includes subcutaneous tissue (eg, excisional biopsy), and relies on the constellation of pathologic and immunophenotypic findings described above in the context of a characteristic clinical picture (",
"    <a class=\"graphic graphic_table graphicRef55385 \" href=\"mobipreview.htm?5/61/6109\">",
"     table 1",
"    </a>",
"    ). Repeat biopsies may be required. Shave biopsies are NOT appropriate because they do not include subcutaneous tissue. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=see_link\">",
"     \"Skin biopsy techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The specific pathologic features of SPTCL are described above. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pathologic features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of SPTCL includes benign and malignant lesions that demonstrate infiltration of the subcutaneous fat with lymphocytes (",
"    <a class=\"graphic graphic_table graphicRef55385 \" href=\"mobipreview.htm?5/61/6109\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Primary cutaneous gamma/delta T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the original World Health Organization (WHO) classification system, SPTCL included both",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    subtypes of T cell lymphoma. However, subsequent studies have noted that patients with these two entities have different pathologic features and a significantly different prognosis. As a result, the current WHO classification system limits SPTCL to tumors expressing",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    T cell receptors. Tumors expressing",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T cell receptors are now categorized as primary cutaneous",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T cell lymphoma (TCL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike SPTCL, cutaneous",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    TCL commonly involves the dermis and epidermis and often causes epidermal ulceration, however, like SPTCL they can sometimes have panniculitis-like morphology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/2\">",
"     2",
"    </a>",
"    ]. The immunophenotype is similar to that of SPTCL in that both express CD3 and cytotoxic molecules (TIA-1, granzyme B,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perforin) and lack expression of CD4. However, unlike SPTCL, primary cutaneous",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    TCL expresses CD56 and TCR gamma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Extranodal NK/T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma is a peripheral T cell lymphoma of either natural killer (NK) or T cell lineage that is associated with Epstein-Barr virus (EBV) infection and typically presents with a mid-facial mass. It sometimes involves the skin, but is never restricted to the subcutaneous tissue. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4249?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While both SPTCL and extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma express CD3 and cytotoxic molecules (TIA-1, granzyme B,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perforin) and lack expression of CD4, extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma differs from SPTCL in that it lacks expression of CD8, expresses CD56, and is uniformly associated with EBV. In addition, T cell receptor genes are typically germline in extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma and are rearranged in SPTCL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Primary cutaneous anaplastic large cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary cutaneous anaplastic large cell lymphoma (ALCL) is a peripheral T cell lymphoma characterized by the diffuse infiltration of the upper and deep dermis and the subcutaneous tissue by large lymphoid cells. Like SPTCL, primary cutaneous ALCL expresses CD3 and cytotoxic molecules (TIA-1, granzyme B,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perforin), but differs in virtually always expressing CD30 and often expressing CD4. T cell receptor genes are rearranged in both. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25337?source=see_link&amp;anchor=H5619109#H5619109\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\", section on 'Primary cutaneous ALCL'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lymphomatoid papulosis and secondary dermal spread of a systemic ALCL should also be considered in the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25337?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mycosis fungoides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycosis fungoides (MF) is a cutaneous T cell lymphoma typically diagnosed using a point-based diagnostic algorithm (",
"    <a class=\"graphic graphic_table graphicRef74457 \" href=\"mobipreview.htm?32/40/33420\">",
"     table 2",
"    </a>",
"    ). Similar to SPTCL, MF expresses CD3, does not express CD56 or demonstrate Epstein-Barr virus infection, and has clonally rearranged T cell receptor genes. MF differs from SPTCL in that it is centered on the dermis and epidermis not the subcutaneous tissue, expresses CD4, and does not express CD8 or cytotoxic molecules (TIA-1, granzyme B,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perforin). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/32/4618?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\", section on 'Immunophenotyping'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Blastic plasmacytoid dendritic cell neoplasm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blastic plasmacytoid dendritic cell neoplasm (also called type 2 dendritic cell acute leukemia, acute plasmacytoid dendritic cell leukemia, or CD4+CD56+ hematodermic neoplasm) is a rare cutaneous neoplasm, which is derived from a precursor of the plasmacytoid dendritic cell and commonly presents with cutaneous nodules or tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/7\">",
"     7",
"    </a>",
"    ]. This tumor can be differentiated from SPTCL based upon the immunophenotype and molecular studies. Unlike SPTCL, T cell receptor genes are germline and the tumor cells express CD4 and CD56 and do not express CD3, CD8, or cytotoxic molecules (TIA-1, granzyme B,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perforin).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Panniculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This clinical findings of SPTCL may resemble other diseases that are characterized by inflammation involving the subcutaneous fat (panniculitis). In comparison with SPTCL, benign panniculitis does not display cytologic atypia and lacks clonal T cell receptor gene rearrangements. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17112?source=see_link\">",
"     \"Panniculitis: Recognition and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In particular, lupus profundus panniculitis typically presents as a firm nodular lesion in patients with systemic lupus erythematosus. Unlike SPTCL, these nodules are often painful and can appear in the mid-dermal, deep dermal, or subcutaneous layers. Histology demonstrates perivascular infiltrates of mononuclear cells plus panniculitis, manifested as hyaline fat necrosis with mononuclear cell infiltration and lymphocytic vasculitis (",
"    <a class=\"graphic graphic_picture graphicRef80683 graphicRef59536 \" href=\"mobipreview.htm?18/55/19319\">",
"     picture 2A-B",
"    </a>",
"    ). In comparison with SPTCL, lupus profundus panniculitis does not display clonality on T cell receptor gene rearrangement studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17112?source=see_link&amp;anchor=H4122269#H4122269\">",
"     \"Panniculitis: Recognition and diagnosis\", section on 'Inflammatory disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of SPTCL is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33065?source=see_link&amp;anchor=H18#H18\">",
"     \"Initial treatment of peripheral T cell lymphoma\", section on 'Subcutaneous panniculitis-like T cell lymphoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27785?source=see_link\">",
"     \"Treatment of relapsed or refractory peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with SPTCL have an indolent course with a five-year overall survival rate of approximately 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/3\">",
"     3",
"    </a>",
"    ]. Occasionally, SPTCL resolves spontaneously. Spread to lymph nodes and other organs is rare.",
"   </p>",
"   <p>",
"    The main predictor of a poor prognosis is presentation with hemophagocytic lymphohistiocytosis (HLH, also called the hemophagocytic syndrome), which, in one series, occurred in 17 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/3\">",
"     3",
"    </a>",
"    ]. Five-year survival was significantly lower in the patients with HLH (46 versus 91 percent). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical presentation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prognostic models used for other types of non-Hodgkin lymphoma have",
"    <strong>",
"     limited",
"    </strong>",
"    applicability to patients with SPTCL. Most patients fall into the low risk category when assessed with either the International prognostic index (IPI) or the Prognostic index for T-cell lymphomas (PIT) (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"mobipreview.htm?17/21/17757\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35126/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, these prognostic tools do not take into account the adverse prognostic effect of HLH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29127?source=see_link&amp;anchor=H17219017#H17219017\">",
"     \"Prognosis of diffuse large B cell lymphoma\", section on 'International Prognostic Index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a peripheral T cell lymphoma derived from a mature cytotoxic T-cell that accounts for less than 1 percent of non-Hodgkin lymphoma. Up to 20 percent of patients will have an associated autoimmune disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients typically present with one or more usually painless subcutaneous nodules or poorly circumscribed indurated plaques involving the extremities or trunk. The skin lesions can demonstrate a waxing and waning course with spontaneous regression and the development of new lesions at different sites. Spread outside the subcutis is extremely unusual. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Less than 20 percent of cases are associated with the hemophagocytic syndrome, an often fatal complication, which may present with high fevers, maculopapular rash, failure to thrive, central nervous system symptoms, hepatosplenomegaly, lymphadenopathy, cytopenias, coagulopathy, abnormal liver function tests, or an extremely high serum ferritin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link\">",
"       \"Hemophagocytic lymphohistiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of SPTCL is made with a deep skin biopsy that includes the subcutis. Repeat biopsies may be required. SPTCL is characterized by a subcutaneous infiltrate of atypical lymphocytes that express CD3, CD8, the",
"      <span class=\"nowrap\">",
"       alpha/beta",
"      </span>",
"      T-cell receptor, and cytotoxic granule proteins (granzyme B, T-cell intracellular antigen (TIA)-1, and perforin) (",
"      <a class=\"graphic graphic_table graphicRef55385 \" href=\"mobipreview.htm?5/61/6109\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef82054 \" href=\"mobipreview.htm?6/28/6598\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathologic features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of SPTCL includes benign and malignant lesions that demonstrate infiltration of the subcutaneous fat with lymphocytes. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with SPTCL appear to have an indolent course with a five-year overall survival rate of approximately 80 percent. The main factor associated with a poor prognosis is the presence of the hemophagocytic syndrome (HPS). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35126/abstract/1\">",
"      Gonzalez CL, Medeiros LJ, Braziel RM, Jaffe ES. T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol 1991; 15:17.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35126/abstract/3\">",
"      Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008; 111:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35126/abstract/4\">",
"      Gallardo F, Pujol RM. Subcutaneous panniculitic-like T-cell lymphoma and other primary cutaneous lymphomas with prominent subcutaneous tissue involvement. Dermatol Clin 2008; 26:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35126/abstract/5\">",
"      Parveen Z, Thompson K. Subcutaneous panniculitis-like T-cell lymphoma: redefinition of diagnostic criteria in the recent World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas. Arch Pathol Lab Med 2009; 133:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35126/abstract/6\">",
"      Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol 1998; 22:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35126/abstract/7\">",
"      Tecchio C, Colato C, Bonifacio M, et al. Plasmacytoid dendritic cell leukemia: a rapidly evolving disease presenting with skin lesions sensitive to radiotherapy plus hyperthermia. Oncologist 2009; 14:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35126/abstract/8\">",
"      A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35126/abstract/9\">",
"      Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103:2474.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4744 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35126=[""].join("\n");
var outline_f34_19_35126=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Primary cutaneous gamma/delta T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Extranodal NK/T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Primary cutaneous anaplastic large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Blastic plasmacytoid dendritic cell neoplasm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Panniculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4744\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4744|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/28/6598\" title=\"picture 1\">",
"      SPTCL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/17/4372\" title=\"picture 2A\">",
"      Skin biopsy lupus profundus I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/17/11536\" title=\"picture 2B\">",
"      Skin biopsy lupus profundus II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4744|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/61/6109\" title=\"table 1\">",
"      PTCL path",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/40/33420\" title=\"table 2\">",
"      Diagnosis early MF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/21/17757\" title=\"table 3\">",
"      Int prognostic index NHL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/47/25337?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4249?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33065?source=related_link\">",
"      Initial treatment of peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17112?source=related_link\">",
"      Panniculitis: Recognition and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29127?source=related_link\">",
"      Prognosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27785?source=related_link\">",
"      Treatment of relapsed or refractory peripheral T cell lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_19_35127="Staphylococcal folliculitis";
var content_f34_19_35127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Staphylococcal folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 508px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Pustules and papules can be seen on this woman's thigh. B) This is a close-up view of Panel A.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35127=[""].join("\n");
var outline_f34_19_35127=null;
var title_f34_19_35128="Autoimmune chronic hepatitis in a 21-year-old - medium power";
var content_f34_19_35128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Autoimmune chronic hepatitis in a 21-year-old man (medium power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is extensive scarring, inflammation, and liver cell necrosis. Many hepatocytes are swollen and vacuolated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35128=[""].join("\n");
var outline_f34_19_35128=null;
var title_f34_19_35129="Pathophysiology and diagnosis of iron overload syndromes";
var content_f34_19_35129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and diagnosis of iron overload syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/19/35129/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/19/35129/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/19/35129/contributors\">",
"     Bruce R Bacon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/19/35129/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/19/35129/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/19/35129/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/19/35129/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/19/35129/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/19/35129/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal iron content of the body is 3 to 4 grams. It exists in the following forms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemoglobin in circulating red cells &mdash; approximately 2.5 grams",
"     </li>",
"     <li>",
"      Iron containing proteins, such as myoglobin, cytochromes, and catalase &mdash; 400 mg",
"     </li>",
"     <li>",
"      Iron bound to transferrin in plasma &mdash; 3 to 7 mg",
"     </li>",
"     <li>",
"      The remainder is storage iron in the form of ferritin or hemosiderin. Adult men have about 1 g of storage iron (mostly in liver, spleen, and bone marrow). Adult women have less storage iron, depending upon the extent of menses, pregnancies, deliveries, lactation, and iron intake, and some may be in negative iron balance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Total body iron content in normal adults is the result of the balance between iron losses and iron absorbed from the diet:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Iron is lost in sweat, shed skin cells, and perhaps some gastrointestinal loss at a rate of approximately 1",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      Premenopausal adult women lose an additional 0.5 to 1.0",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of iron because of menses.",
"     </li>",
"     <li>",
"      Such iron losses are usually balanced by the absorption of approximately 10 percent of the 10 to 20 mg of iron in the diet in Western affluent societies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21082?source=see_link\">",
"       \"Regulation of iron balance\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased absorption of dietary (or medicinal) iron, or iron from multiple transfusions in excess of blood loss will ultimately result in iron overload. The pathophysiology and approach to diagnosis of such iron overload states will be reviewed here.",
"   </p>",
"   <p>",
"    The clinical manifestations of hereditary hemochromatosis (HH), the prototypic chronic iron overload syndrome, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=see_link\">",
"     \"Clinical manifestations of hereditary hemochromatosis\"",
"    </a>",
"    .) These topics are also discussed in an official guideline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/2\">",
"     2",
"    </a>",
"    ] issued by the American Association for the Study of Liver Diseases, which can be accessed through the AASLD web site at:",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     www.aasld.org/practiceguidelines/Pages/default.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IRON TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The iron replete state is characterized by increased production of ferritin to permit adequate storage along with decreased production of the transferrin receptor to minimize further iron entry into the cell. These responses are mediated by the iron responsive element binding protein (IRE-BP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/3\">",
"     3",
"    </a>",
"    ]. The iron responsive element itself consists of a loop configuration of nucleotides found on the mRNA for ferritin and the transferrin receptor.",
"   </p>",
"   <p>",
"    In the presence of iron, the IRE-BP detaches from ferritin mRNA, allowing more ferritin to be synthesized. IRE-BP serves a different function on transferrin receptor mRNA, stabilizing it so that more transferrin receptor is synthesized. Thus, detachment of IRE-BP when the cell is iron replete destabilizes the mRNA and reduces transferrin receptor synthesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21082?source=see_link\">",
"     \"Regulation of iron balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As the body content (burden) of iron increases, the saturation of circulating transferrin with iron increases, resulting in the production of increased amounts of nontransferrin bound iron (labile plasma iron) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], and the off-loading of iron, especially to cells with high levels of transferrin receptors (eg, heart, liver, thyroid, gonads, and pancreatic islets), resulting in such complications as cardiomyopathy, cirrhosis, endocrinopathy, and diabetes.",
"   </p>",
"   <p>",
"    The excess iron in these cells may act as a Fenton agent, catalyzing the Haber-Weiss reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; H2O2 &nbsp;+ &nbsp;Fe(2+) &nbsp; &mdash;&gt; &nbsp; OH- &nbsp;+ &nbsp;Fe(3+) &nbsp;+ &nbsp;OH&bull; (hydroxyl radical)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; O2- (superoxide anion) &nbsp;+ &nbsp;Fe (3+) &nbsp; &mdash;&gt; &nbsp; O2 &nbsp;+ &nbsp;Fe(2+)",
"   </p>",
"   <p>",
"    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"    <strong>",
"     SUM:",
"    </strong>",
"    H2O2 &nbsp;+ &nbsp;O2- &nbsp; &mdash;&gt; &nbsp; O2 &nbsp;+ &nbsp;OH- &nbsp;+ &nbsp;OH&bull;",
"   </p>",
"   <p>",
"    The reactive oxygen species produced by these reactions presumably oxidize lipids, proteins, and perhaps RNA and DNA, thereby causing tissue damage and subsequently fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. These reactions are assumed to contribute to the clinical manifestations of the iron overload syndromes which have been best characterized in patients with hereditary hemochromatosis and beta thalassemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=see_link\">",
"     \"Clinical manifestations of hereditary hemochromatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathophysiology of beta thalassemia\", section on 'Oxidant injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some of the toxicity of iron may be abrogated by the body's antioxidant defenses, such as glutathione-S-transferase (GST) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/8\">",
"     8",
"    </a>",
"    ]. As an example, in a study of 172 patients with classical hereditary hemochromatosis, the GSTP1",
"    <span class=\"nowrap\">",
"     Val/Val",
"    </span>",
"    genotype, which has a markedly reduced capability of conjugating certain toxins with glutathione [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/9\">",
"     9",
"    </a>",
"    ], was significantly more common in patients with, than in those without, cirrhosis (OR 3.8, 95% CI 1.2-13) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because there is no normal mechanism for increasing iron excretion once it has been absorbed into the body, iron overload will ensue in the following settings (",
"    <a class=\"graphic graphic_table graphicRef54284 \" href=\"mobipreview.htm?16/43/17084\">",
"     table 1",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/13/2266?source=see_link\">",
"     \"Genetics of hereditary hemochromatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=see_link\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\"",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An increase in iron absorption when iron intake is normal, as in the various genetic forms of hereditary hemochromatosis",
"     </li>",
"     <li>",
"      A massive increase in oral iron intake, as in some forms of African iron overload",
"     </li>",
"     <li>",
"      Iron overload secondary to multiple blood transfusions (eg, sickle cell disease, beta thalassemia major, aplastic anemia, myelodysplasia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Homozygous HH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with homozygous hereditary hemochromatosis (HH), the absorption of heme iron is not regulated by the content of iron stores, as measured by the serum ferritin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/14\">",
"     14",
"    </a>",
"    ]. Subjects with HH may absorb 2 to 4 mg of iron per day from heme and non-heme iron sources, rather than the normal value of 1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    needed in males to balance iron loss from sloughed skin and minor gastrointestinal blood loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this example, absorption of 4",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (3",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in excess of needs) would lead to net iron accumulation of approximately 1 g per year, or more than 20 g of iron from the end of the adolescent growth spurt in males to age 40 or 50. Subjects with this degree of iron overload are poised to develop the clinical features of HH. Women become symptomatic later in life, because of the extra iron losses associated with menses, delivery, and lactation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methods used to establish the presence of iron overload (increased body iron burden) include serum iron studies, various radiologic techniques, liver biopsy, and assessment of the response to phlebotomy or chelation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/15\">",
"     15",
"    </a>",
"    ]. Increased suspicion of iron overload can also come from a positive family history for iron overload",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of iron overload, in the absence of transfusional iron overload, is almost always HH. Thus, genetic testing for HH should be performed in all patients suspected of having this disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/13/2266?source=see_link\">",
"     \"Genetics of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Routine iron studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three serum measurements for the diagnosis of iron overload, each of which is associated with potential sources of error, as will be discussed in this section.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Plasma (or serum) iron concentration",
"      </strong>",
"      &mdash; normal 60 to 150",
"      <span class=\"nowrap\">",
"       microg/dL",
"      </span>",
"      (10.7 to 26.8",
"      <span class=\"nowrap\">",
"       micromoles/L)",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       Transferrin concentration (plasma total iron binding capacity, TIBC)",
"      </strong>",
"      &mdash; normal 300 to 360",
"      <span class=\"nowrap\">",
"       microg/dL",
"      </span>",
"      (53.7 to 64.4",
"      <span class=\"nowrap\">",
"       micromoles/L).",
"      </span>",
"      The ratio of plasma iron to transferrin permits calculation of the transferrin saturation &mdash; normal 20 to 50 percent.",
"     </li>",
"     <li>",
"      <strong>",
"       Plasma ferritin",
"      </strong>",
"      &mdash; normal 40 to 200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (40 to 200",
"      <span class=\"nowrap\">",
"       microg/L;",
"      </span>",
"      89.9 to 449.4",
"      <span class=\"nowrap\">",
"       picomoles/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less commonly used is the unsaturated iron binding capacity (UIBC), which is the difference between the TIBC and serum iron. In severe iron overload states transferrin saturation can approach 100 percent and the UIBC can approach zero.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cutoff levels for screening purposes",
"    </span>",
"    &nbsp;&mdash;&nbsp;When body iron burdens are increased in normal subjects, plasma iron levels increase, plasma transferrin saturation rises, as does the concentration of ferritin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/3\">",
"     3",
"    </a>",
"    ]. A fasting transferrin saturation &ge;60 percent in men or &ge;50 percent in women has been accurate in detecting over 90 percent of patients with homozygous HH who have clinical symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    documented iron overload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/13,17-20\">",
"     13,17-20",
"    </a>",
"    ]. However, many investigators have advocated using a lower \"cutoff\" value of 45 percent transferrin saturation for both men and women, which will lead to fewer patients being missed (ie, those with the disease but without symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    iron overload), at the expense of an increased false positive rate.",
"   </p>",
"   <p>",
"    Increased iron also stimulates the hepatic production and release of ferritin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/21\">",
"     21",
"    </a>",
"    ]. As a result, a plasma ferritin concentration above 300",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in men and 200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in women provides further support for the diagnosis of iron overload, provided that acute inflammation is not also present (see below). An elevated plasma ferritin is generally less sensitive than the transferrin saturation in screening for HH because a greater degree of iron overload is required to raise the ferritin concentration than to increase transferrin saturation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The accuracy of the above measures of iron status was evaluated in a study involving more than 30,000 adults attending a health clinic who agreed to undergo blood testing and DNA analysis for HFE mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. A transferrin saturation &ge;50 percent had a sensitivity of only 0.57 and a specificity of 0.98 for the detection of C282Y homozygosity. A ferritin level &ge;200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    had a sensitivity of 0.66 and specificity of 0.85 (",
"    <a class=\"graphic graphic_table graphicRef52869 \" href=\"mobipreview.htm?15/52/16204\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2275080\">",
"    <span class=\"h4\">",
"     AASLD screening guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2011 guidelines from the American Association for the Study of Liver Diseases regarding the appropriate cutoff levels for transferrin saturation (greater than 45 percent) and serum ferritin (greater than 200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in men and greater than 150",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in women) for screening patients with iron overload are in general agreement with the above-noted values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Sources of error",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are potential sources of error with each of these tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As discussed above, depending upon the cutoff used, the transferrin saturation may miss a substantial proportion of patients who are homozygous for HFE mutations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/22\">",
"       22",
"      </a>",
"      ]. A similar problem occurs in subjects with the newly described syndrome of liver iron overload with normal transferrin saturation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=see_link\">",
"       \"Iron overload syndromes other than hereditary hemochromatosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ferritin levels and transferrin saturation are generally higher in Asians and Pacific Islanders than in their white counterparts, although there was little evidence of significant iron overload among Asians as assessed by quantitative phlebotomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Not all subjects with classical HH have signs and symptoms of iron overload when first discovered via genetic screening. In one study, for example, laboratory and genetic screening of relatives of 53 previously identified probands uncovered 95 C282Y homozygotes, of whom 20 percent did not have elevated ferritin levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/30\">",
"       30",
"      </a>",
"      ]. An even larger percent of subjects first uncovered by population screening exhibit no signs and symptoms of the disease (ie, low disease penetrance). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12535?source=see_link\">",
"       \"Screening for hereditary hemochromatosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As the above findings illustrate, relying on plasma testing for the diagnosis of iron overload is associated with both false negative and false positive results. Bone marrow aspiration and iron stain are not helpful in this setting, since marrow macrophages may not show iron loading even in severe classical HH.",
"   </p>",
"   <p>",
"    Given that the vast majority of patients discovered to have HH through regular medical care or screening have neither severe iron overload nor cirrhosis, it has been suggested that screening should be limited to obtaining serum ferritin alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], as only patients with HH and serum ferritin levels &gt;1000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    have been shown to be at increased risk for the development of cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Prospective studies to show the risks, benefits, and cost- effectiveness of this approach will be required before this can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14968470\">",
"    <span class=\"h3\">",
"     High levels of ferritin in the absence of iron overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ferritin production and plasma ferritin concentrations are increased in the absence of iron overload in certain liver diseases (including chronic viral hepatitis, alcoholic liver disease, and nonalcoholic steatohepatitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/35-37\">",
"     35-37",
"    </a>",
"    ] and by inflammatory cytokines (such as interleukin-1 and tumor necrosis factor), since ferritin is an acute phase reactant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/17,21\">",
"     17,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, inflammatory diseases, the metabolic syndrome (ie, abdominal obesity, dyslipidemia, hypertension, insulin resistance), and malignancy can raise the plasma ferritin concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/38-42\">",
"     38-42",
"    </a>",
"    ]. As a result, in one study the positive predictive value of an elevated plasma or serum ferritin when screening for HH was much lower (20 percent) than that of an increased transferrin saturation (80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2234669\">",
"    <span class=\"h4\">",
"     Extremely high levels of ferritin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extremely high levels of ferritin",
"    <strong>",
"    </strong>",
"    are generally seen",
"    <strong>",
"     chronically",
"    </strong>",
"    only in subjects with one of the genetic forms of hemochromatosis and in those who have received multiple red cell transfusions.",
"    <strong>",
"     Acute",
"    </strong>",
"    onset of extremely high levels of ferritin may be seen in juvenile idiopathic arthritis, systemic lupus erythematosus, opportunistic infection in immunocompromised hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/44\">",
"     44",
"    </a>",
"    ], and hemophagocytic lymphohistiocytosis (HLH). As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children, a ferritin &gt;10,000",
"      <span class=\"nowrap\">",
"       micrograms/L",
"      </span>",
"      was found to be 90 percent sensitive and 96 percent specific for the diagnosis of HLH. As this condition is potentially fatal if not rapidly diagnosed and treated, HLH should be an important part of the differential diagnosis in this setting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link&amp;anchor=H24#H24\">",
"       \"Hemophagocytic lymphohistiocytosis\", section on 'Ferritin levels'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients infected with HIV constitute 16 to 36 percent of individuals with serum ferritin levels &ge;1000",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. Such elevations appear to be a marker for relatively advanced disease with low CD4 counts, the presence of opportunistic infection (eg, disseminated histoplasmosis, mycobacterial infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/47\">",
"       47",
"      </a>",
"      ]), reactive hemophagocytosis, and limited survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/48\">",
"       48",
"      </a>",
"      ]. In a review of eight HIV-infected patients hospitalized with fever and extreme hyperferritinemia (eg, &gt;10,000",
"      <span class=\"nowrap\">",
"       ng/mL),",
"      </span>",
"      all had concurrent opportunistic infection, with the most common infectious agent being Histoplasma capsulatum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a rare genetic condition, high levels of ferritin are associated with bilateral cataracts in otherwise asymptomatic individuals. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/13/2266?source=see_link&amp;anchor=H19#H19\">",
"       \"Genetics of hereditary hemochromatosis\", section on 'Hyperferritinemia without iron overload'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link&amp;anchor=H33#H33\">",
"       \"Hemophagocytic lymphohistiocytosis\", section on 'Macrophage activation syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     CT, MRI, and SQUID techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DEFINITIVE TEST for the diagnosis of hepatic iron overload and its consequences (eg, cirrhosis, hepatocellular carcinoma) is liver biopsy (see below), although noninvasive imaging studies, such as CT as well as T2* and R2* measurements by MRI have become increasingly accurate for determining both hepatic as well as cardiac iron deposition (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69367 \" href=\"mobipreview.htm?35/31/36337\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56593 \" href=\"mobipreview.htm?2/45/2769\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/15,50-59\">",
"     15,50-59",
"    </a>",
"    ]. An important point to remember is that the degrees of hepatic and myocardial iron overload may be discordant in an individual patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of hepatic iron concentration as determined by magnetic susceptometry using a Superconducting Quantum Interference Device (SQUID) yields results that are quantitatively equivalent to those obtained by chemical analysis of liver biopsy tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. However, because of their complexity, expense, and requirement for liquid helium cooling, only about four instruments are available worldwide for clinical use.",
"   </p>",
"   <p>",
"    Quantitative phlebotomy, as described below, is an alternative method for determining the presence or absence of iron overload in non-anemic patients, such as those with hereditary hemochromatosis. However, in contrast to liver biopsy, quantitative phlebotomy and imaging techniques provide no information about the cellular location of the removed iron, or the presence or absence of hepatic fibrosis, cirrhosis, or hepatocellular carcinoma, important complications of iron overload.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Liver biopsy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance evaluation for hepatic iron concentration is improved compared with programs that were used several years ago. However, expertise in such evaluation is not universally available, and, in any case, will not detect cellular liver damage due to iron overload. Accordingly, most hepatologists rely on liver biopsy to determine severity of liver disease in patients with elevated liver enzymes and ferritin levels &gt;1,000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for either C282Y homozygotes or compound heterozygotes.",
"   </p>",
"   <p>",
"    In the past, liver biopsy was used to fully establish a diagnosis of HH. However, we now rely on genetic testing for making the diagnosis of a hereditary form of hemochromatosis and magnetic resonance imaging, when such expertise is available, for a non-invasive estimation of hepatic and cardiac iron stores. We would still employ liver biopsy to determine severity of disease in patients who are at higher risk for more advanced liver involvement (eg, presence or absence of inflammation, fibrosis, cirrhosis, or hepatocellular carcinoma).",
"   </p>",
"   <p>",
"    Parenchymal iron loading can be demonstrated by Perls' Prussian blue staining of a liver biopsy specimen, while standard histologic examination can detect the presence of fibrosis (",
"    <a class=\"graphic graphic_picture graphicRef70985 graphicRef50096 \" href=\"mobipreview.htm?30/58/31658\">",
"     picture 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/27,62\">",
"     27,62",
"    </a>",
"    ]. Hepatic tissue can also be directly analyzed for iron content, the majority of which is nonheme iron (",
"    <a class=\"graphic graphic_figure graphicRef55632 \" href=\"mobipreview.htm?41/44/42701\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/36/43591?source=see_link&amp;anchor=H8#H8\">",
"     \"Long-term management of the thalassemic patient after hematopoietic cell transplantation\", section on 'Estimation of total body iron and strategy for iron removal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hepatic iron content is preferably reported as micromoles of iron per gram dry weight of liver. Normal values are &lt;36",
"    <span class=\"nowrap\">",
"     micromol/g,",
"    </span>",
"    while values &gt;71",
"    <span class=\"nowrap\">",
"     micromol/g",
"    </span>",
"    are highly suggestive of homozygous HH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/63\">",
"     63",
"    </a>",
"    ]. This value can be divided by the subject's age in years to give the hepatic iron index (HII); a value &ge;1.9 is consistent with, but not diagnostic of homozygous HH.",
"   </p>",
"   <p>",
"    In a large multicenter series, for example, the HII was &ge;1.9 in 51 of 55 patients who met clinical and histologic criteria for homozygous HH but in none of 454 patients with other liver diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/63\">",
"     63",
"    </a>",
"    ]. However, with the increased use of screening tests and genetic testing, many patients with HH will be discovered before significant iron overload has occurred. Accordingly, it has been estimated that 15 to 25 percent of patients with HH will have an HII below 1.9. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33748?source=see_link\">",
"     \"Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Patients who may not need a liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A liver biopsy may not be necessary for all patients with HH. An exception to the general recommendation for liver biopsy may arise when the diagnosis has been clearly established based upon genetic testing (see below), and there is a low likelihood of finding significant hepatic fibrosis or cirrhosis, which is associated with increased mortality even after iron depletion.",
"   </p>",
"   <p>",
"    In one study, for example, clinical variables were evaluated in 197 French patients who were homozygous for the C282Y mutation and had undergone a liver biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/33\">",
"     33",
"    </a>",
"    ]. On multivariate analysis, the presence of a normal serum aspartate aminotransferase (AST) concentration, a serum ferritin concentration &lt;1000",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and the absence of hepatomegaly were highly predictive of the absence of fibrosis on liver histology (negative predictive value of 100 percent). This model was validated in a separate cohort of 113 patients in Canada, with similar results.",
"   </p>",
"   <p>",
"    However, we have seen patients with HH who had hepatic fibrosis and even cirrhosis despite a serum ferritin concentration that was less than 1000",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Thus, we have not incorporated this cutoff into our practice. Instead, we proceed directly to phlebotomy without a liver biopsy in patients who have all of the following characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &lt;40",
"     </li>",
"     <li>",
"      Homozygous C282Y mutation",
"     </li>",
"     <li>",
"      Presence of indirect markers of iron overload (ie, elevated transferrin saturation and elevated serum or plasma ferritin)",
"     </li>",
"     <li>",
"      Normal liver enzymes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A later study suggested that age was not an independent predictor of fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/34\">",
"     34",
"    </a>",
"    ]. The only significant independent predictors were abnormal serum liver enzymes and a serum ferritin level &ge;1000",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    The authors proposed, and the 2011 Practice Guidelines of the AASLD have agreed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/26\">",
"     26",
"    </a>",
"    ], that a liver biopsy was unnecessary for determining whether fibrosis is present in patients who do not drink alcohol, have a serum ferritin &lt;1000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and normal serum AST and ALT levels, and are C282Y homozygotes or",
"    <span class=\"nowrap\">",
"     C282Y/H63D",
"    </span>",
"    compound heterozygotes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Endomyocardial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial iron content cannot be predicted from serum ferritin or liver iron and identification of ventricular dysfunction detects only advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/56\">",
"     56",
"    </a>",
"    ]. As mentioned above, cardiac magnetic resonance has been increasingly employed to detect myocardial iron overload so biopsy confirmation is rarely required. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'CT, MRI, and SQUID techniques'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the above-noted evaluations are nondiagnostic, endomyocardial biopsy can be useful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7592?source=see_link&amp;anchor=H14#H14\">",
"     \"Endomyocardial biopsy\", section on 'Chronic DCM'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Response to phlebotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there are reasons why a liver biopsy cannot be performed but iron overload is suspected, one can clinically confirm the presence of iron overload in most patients by determining the number of weekly 500 mL phlebotomies, each of which removes 200 to 250 mg of elemental iron, which are required to produce iron deficient erythropoiesis. This procedure is called quantitative phlebotomy.",
"   </p>",
"   <p>",
"    Normal men have approximately 1 g of iron stores. As a result, four to five phlebotomies over a four to eight week period will produce an iron deficient state, characterized by hypochromic, microcytic anemia. In contrast, patients with significant iron loading usually have at least 5 g (and often 20 g or more) of iron stores, requiring at least 20 units of phlebotomy to induce iron deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/13,28\">",
"     13,28",
"    </a>",
"    ]. The procedure we use is to phlebotomize 500 mL one to two times each week until the patient's hemoglobin concentration has fallen to about 12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and the red blood cell mean corpuscular volume has fallen from normal (80 to 96 fL) to values in the range of 75 to 80 fL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/13\">",
"     13",
"    </a>",
"    ]. The iron loss required to achieve these changes is then calculated. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35543?source=see_link\">",
"     \"Mean corpuscular volume\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18952?source=see_link\">",
"     \"Treatment of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some patients with HH do not have such pronounced iron overload. In one series of 40 patients, for example, four (all women, three less than 30 years of age) with clearly defined HH developed signs of iron depletion after the removal of only 8 to 11 units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, newly diagnosed patients with HH will be active blood donors. However, routine blood donation (eg, one unit every eight weeks) does not, on average, decrease the severity of iron overload, presumably since enough iron is absorbed during the interval between donations to re-establish pre-donation increased iron burdens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Genetic testing for HH",
"    </span>",
"    &nbsp;&mdash;&nbsp;We no longer have to rely entirely on the phenotypic expression of HH now that genetic testing has become available for diagnosing some forms of this disorder. All patients being evaluated for HH should have C282Y and H63D mutation analysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/13/2266?source=see_link\">",
"     \"Genetics of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a",
"      <span class=\"nowrap\">",
"       C282Y/C282Y",
"      </span>",
"      genotype are homozygous for HH, and are candidates for having symptomatic iron overload",
"     </li>",
"     <li>",
"      Patients with a",
"      <span class=\"nowrap\">",
"       C282Y/wild",
"      </span>",
"      type (wt) genotype are heterozygous for HH (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Iron status in HH heterozygotes'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Patients with a",
"      <span class=\"nowrap\">",
"       C282Y/H63D",
"      </span>",
"      genotype (ie, one allele with each mutation) have a compound heterozygote genotype. Approximately 60 percent of compound heterozygotes have an intermediate degree of iron loading, and 35 percent have normal iron burdens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional mutations leading to iron overload within and outside of the HFE locus continue to be uncovered; thus the",
"    <span class=\"nowrap\">",
"     genotype/phenotype",
"    </span>",
"    correlation has not been fully elucidated. Accordingly, the significance of the",
"    <span class=\"nowrap\">",
"     H63D/wild",
"    </span>",
"    type or",
"    <span class=\"nowrap\">",
"     H63D/H63D",
"    </span>",
"    genotypes is still being determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/13/2266?source=see_link&amp;anchor=H13#H13\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Other gene defects leading to iron overload or high ferritin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Determination of HFE genotype may be particularly useful in patients with known types of liver disease and suspected iron overload (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Distinction from alcoholic liver disease'",
"    </a>",
"    below). These patients may have elevated serum iron studies without significantly elevated hepatic iron burdens. This issue was evaluated in a study that included 66 patients with HH and 132 patients with other liver diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/64\">",
"     64",
"    </a>",
"    ]. All patients underwent routine blood chemistries, HFE genotype determination, and liver biopsy.",
"   </p>",
"   <p>",
"    The majority of patients with HH diagnosed on the basis of iron studies and liver biopsy (91 percent) were C282Y homozygotes, including six patients in whom HH had not been originally suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/64\">",
"     64",
"    </a>",
"    ]. Another clinically important observation was that 10 of 66 patients (15 percent) with HH had a hepatic iron index (HII) of less than 1.9",
"    <span class=\"nowrap\">",
"     mmol/kg",
"    </span>",
"    per year. This suggests that a lower HII value does not exclude HH. However, it is uncertain whether these patients have the same risk of complications as patients in whom HH is diagnosed on the basis of an HII &gt;1.9",
"    <span class=\"nowrap\">",
"     mmol/kg",
"    </span>",
"    per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A listing of genetic testing laboratories is available through GeneTests, an NIH-funded medical genetics information resource [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Iron status in HH heterozygotes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subjects who are heterozygous for HH are at much less risk of iron overload. The iron status in these individuals has been assessed in a series of 1058 patients from 202 pedigrees [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/70\">",
"     70",
"    </a>",
"    ]. The following findings were noted when compared with nonaffected control family members:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean transferrin saturation was significantly increased in both men (38 versus 30 percent) and women (31 versus 25 percent). The values were above 62 percent in 4 percent of males and above 50 percent in 8 percent of females, thresholds usually associated with the homozygous HH genotype.",
"     </li>",
"     <li>",
"      The serum ferritin concentrations were only slightly increased in affected heterozygotes when compared with nonaffected control family members. The upper 95 percent confidence limits for ferritin were less than 160",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in heterozygous males and less than 98",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in heterozygous females. No male or female heterozygote had a ferritin level exceeding 1000",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"     </li>",
"     <li>",
"      Liver biopsy was performed in 39 patients. Six were abnormal but five had associated conditions (eg, hepatitis, alcohol abuse). Thus, liver disease due to HH alone is rare in heterozygotes, although these patients may be at some long-term risk for the complications of iron overload. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=see_link\">",
"       \"Clinical manifestations of hereditary hemochromatosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations indicate that a small proportion of patients heterozygous for HH may be misclassified as homozygous based upon serum testing alone. The correct diagnosis can be established by analysis of the C282Y and H63D HFE mutations. When the hepatic iron index is calculated and is between 1.5 and 1.9, it is not possible without genetic testing to differentiate between heterozygotes and homozygotes with decreased phenotypic expression or previous blood loss or donation. We recommend that these patients be treated as if they were homozygous for HH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33748?source=see_link\">",
"     \"Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Distinction from alcoholic liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common differential diagnostic alternative to HH is chronic liver disease due to alcohol abuse. The clinical picture is one of a heavy drinker, perhaps of iron-containing fortified wines, who has cirrhosis and may have had a portacaval shunt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/71\">",
"     71",
"    </a>",
"    ]. Liver biopsy in such patients, in addition to showing steatosis and cirrhosis, occasionally shows a modest increase in Perls' Prussian blue staining for iron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/37\">",
"     37",
"    </a>",
"    ]. Further diagnostic confusion occurs because the serum ferritin concentration is often elevated (to 600",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or more) in this disorder and other forms of liver disease, and the serum transferrin saturation may reach or exceed 60 percent, perhaps because alcohol suppresses liver transferrin synthesis.",
"   </p>",
"   <p>",
"    However, critical evaluation has revealed two major differences between alcoholic liver disease and HH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic iron levels are relatively normal, well below the values that are usually found in homozygous HH (ie, &gt;71",
"      <span class=\"nowrap\">",
"       &micro;mol/g",
"      </span>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35129/abstract/37,63,70,72\">",
"       37,63,70,72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Quantitative phlebotomy shows that most of patients with alcoholic liver disease have less than 4 g of mobilizable iron.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic testing may be helpful for establishing the correct diagnosis (see above). Therapy in such patients is directed at the substance abuse and the cirrhosis, not at iron removal. An exception is the patient with alcohol abuse and symptomatic porphyria cutanea tarda, in whom iron removal via phlebotomy, along with abstention from alcohol, often results in a clinical remission. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28458?source=see_link&amp;anchor=H4527446#H4527446\">",
"     \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/15/40179?source=see_link\">",
"       \"Patient information: Hemochromatosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/41/2709?source=see_link\">",
"       \"Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2563985\">",
"    <span class=\"h2\">",
"     Causes of iron overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because there is no normal mechanism for increasing iron excretion once it has been absorbed into the body, iron overload will ensue in the following settings (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Causes'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased iron absorption when iron intake is normal, as in the genetic forms of hereditary hemochromatosis",
"     </li>",
"     <li>",
"      A massive increase in oral iron intake, as in some forms of African iron overload",
"     </li>",
"     <li>",
"      Multiple blood transfusions (eg, sickle cell disease, beta thalassemia major, aplastic anemia, myelodysplastic syndrome)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2563874\">",
"    <span class=\"h2\">",
"     Suspecting iron overload from iron studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"local\" href=\"#H7\">",
"     'Cutoff levels for screening purposes'",
"    </a>",
"    above)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A fasting transferrin saturation &ge;60 percent in men or &ge;50 percent in women is accurate in detecting over 90 percent of patients with homozygous HH who have clinical symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      documented iron overload.",
"     </li>",
"     <li>",
"      Many investigators, including a Practice Guideline from the American Association for the Study of Liver Disease have advocated using a lower \"cutoff\" value of 45 percent transferrin saturation for both men and women, which will lead to fewer patients being missed, although at the expense of an increased false positive rate (",
"      <a class=\"graphic graphic_algorithm graphicRef64293 \" href=\"mobipreview.htm?6/49/6943\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Some institutions have developed expertise in the use of MRI techniques for assessing cardiac and liver iron, although MRI techniques cannot detect tissue or cellular damage due to tissue iron overload. If direct or indirect markers of liver disease are present (ie, subjects who drink alcohol, serum ferritin &gt;1000",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      abnormal serum AST and ALT levels), we suggest that those diagnosed with the",
"      <span class=\"nowrap\">",
"       C282Y/C282Y",
"      </span>",
"      HFE genotype should undergo a liver biopsy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Liver biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest screening of all first degree relatives of patients with the",
"      <span class=\"nowrap\">",
"       C282Y/C282Y",
"      </span>",
"      HFE genotype, although the vast majority of those so diagnosed may not need immediate treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12535?source=see_link&amp;anchor=H8#H8\">",
"       \"Screening for hereditary hemochromatosis\", section on 'Genetic testing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2564098\">",
"    <span class=\"h2\">",
"     Suspecting iron overload from serial phlebotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a liver biopsy cannot be performed and iron overload is suspected, one can confirm the presence of iron overload by determining the number of weekly 500 mL phlebotomies required to produce iron deficient erythropoiesis. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Response to phlebotomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal men have approximately 1 g of iron stores; four to five phlebotomies will produce an iron deficient state.",
"     </li>",
"     <li>",
"      Most patients with alcoholic liver disease have less than 4 g of mobilizable iron. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Distinction from alcoholic liver disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with significant iron loading usually have at least 5 g (and often 20 g or more) of iron stores, requiring at least 20 units of phlebotomy to induce iron deficiency.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/1\">",
"      Cook JD, Flowers CH, Skikne BS. The quantitative assessment of body iron. Blood 2003; 101:3359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/2\">",
"      Tavill AS, American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association. Diagnosis and management of hemochromatosis. Hepatology 2001; 33:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/3\">",
"      Theil EC. The IRE (iron regulatory element) family: structures which regulate mRNA translation or stability. Biofactors 1993; 4:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/4\">",
"      Sahlstedt L, Ebeling F, von Bonsdorff L, et al. Non-transferrin-bound iron during allogeneic stem cell transplantation. Br J Haematol 2001; 113:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/5\">",
"      Esposito BP, Breuer W, Sirankapracha P, et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003; 102:2670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/6\">",
"      Hebbel RP. Auto-oxidation and a membrane-associated 'Fenton reagent': a possible explanation for development of membrane lesions in sickle erythrocytes. Clin Haematol 1985; 14:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/7\">",
"      Le Lan C, Lor&eacute;al O, Cohen T, et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 2005; 105:4527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/8\">",
"      Hayes JD, McLellan LI. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res 1999; 31:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/9\">",
"      Berhane K, Widersten M, Engstr&ouml;m A, et al. Detoxication of base propenals and other alpha, beta-unsaturated aldehyde products of radical reactions and lipid peroxidation by human glutathione transferases. Proc Natl Acad Sci U S A 1994; 91:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/10\">",
"      Stickel F, Osterreicher CH, Datz C, et al. Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch Intern Med 2005; 165:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/11\">",
"      Smith LH Jr. Overview of hemochromatosis. West J Med 1990; 153:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/12\">",
"      Smith LH Jr. Pumping iron. West J Med 1995; 162:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/13\">",
"      Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med 1993; 328:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/14\">",
"      Lynch SR, Skikne BS, Cook JD. Food iron absorption in idiopathic hemochromatosis. Blood 1989; 74:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/15\">",
"      Jensen PD. Evaluation of iron overload. Br J Haematol 2004; 124:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/16\">",
"      Acton RT, Barton JC, Passmore LV, et al. Accuracy of family history of hemochromatosis or iron overload: the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 2008; 6:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/17\">",
"      Pippard MJ. Detection of iron overload. Lancet 1997; 349:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/18\">",
"      Edwards CQ, Griffen LM, Goldgar D, et al. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/19\">",
"      Dadone MM, Kushner JP, Edwards CQ, et al. Hereditary hemochromatosis. Analysis of laboratory expression of the disease by genotype in 18 pedigrees. Am J Clin Pathol 1982; 78:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/20\">",
"      Milman N. Iron status markers in hereditary haemochromatosis: distinction between individuals being homozygous and heterozygous for the haemochromatosis allele. Eur J Haematol 1991; 47:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/21\">",
"      Tran TN, Eubanks SK, Schaffer KJ, et al. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood 1997; 90:4979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/22\">",
"      Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000; 133:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/23\">",
"      Koziol JA, Felitti VJ, Beutler E. The effect of HFE genotypes on measurements of iron overload. Ann Intern Med 2002; 137:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/24\">",
"      Schmitt B, Golub RM, Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med 2005; 143:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/25\">",
"      Qaseem A, Aronson M, Fitterman N, et al. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 143:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/26\">",
"      Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/27\">",
"      Bacon BR. Diagnosis and management of hemochromatosis. Gastroenterology 1997; 113:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/28\">",
"      Moirand R, Mortaji AM, Lor&eacute;al O, et al. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997; 349:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/29\">",
"      Harris EL, McLaren CE, Reboussin DM, et al. Serum ferritin and transferrin saturation in Asians and Pacific Islanders. Arch Intern Med 2007; 167:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/30\">",
"      Lazarescu A, Snively BM, Adams PC. Phenotype variation in C282Y homozygotes for the hemochromatosis gene. Clin Gastroenterol Hepatol 2005; 3:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/31\">",
"      Waalen J, Felitti VJ, Gelbart T, Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood 2008; 111:3373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/32\">",
"      Barton JC. Ferritin &gt;1000: grand for hemochromatosis screening. Blood 2008; 111:3309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/33\">",
"      Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998; 115:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/34\">",
"      Morrison ED, Brandhagen DJ, Phatak PD, et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003; 138:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/35\">",
"      Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/36\">",
"      Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/37\">",
"      Chapman RW, Morgan MY, Laulicht M, et al. Hepatic iron stores and markers of iron overload in alcoholics and patients with idiopathic hemochromatosis. Dig Dis Sci 1982; 27:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/38\">",
"      Finch CA, Bellotti V, Stray S, et al. Plasma ferritin determination as a diagnostic tool. West J Med 1986; 145:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/39\">",
"      Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/40\">",
"      Zimmermann A, Zimmermann T, Schattenberg J, et al. Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome. Eur J Intern Med 2011; 22:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/41\">",
"      H&auml;m&auml;l&auml;inen P, Saltevo J, Kautiainen H, et al. Erythropoietin, ferritin, haptoglobin, hemoglobin and transferrin receptor in metabolic syndrome: a case control study. Cardiovasc Diabetol 2012; 11:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/42\">",
"      Goot K, Hazeldine S, Bentley P, et al. Elevated serum ferritin - what should GPs know? Aust Fam Physician 2012; 41:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/43\">",
"      Conte D, Manachino D, Colli A, et al. Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. Ann Intern Med 1998; 128:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/44\">",
"      Hsia CC, Lazo-Langner A. Histoplasmosis-induced pancytopenia. Blood 2012; 120:2937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/45\">",
"      Lee MH, Means RT Jr. Extremely elevated serum ferritin levels in a university hospital: associated diseases and clinical significance. Am J Med 1995; 98:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/46\">",
"      Kirn DH, Fredericks D, McCutchan JA, et al. Serum ferritin levels correlate with disease activity in patients with AIDS and disseminated histoplasmosis. Clin Infect Dis 1995; 21:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/47\">",
"      Koduri PR, Carandang G, DeMarais P, Patel AR. Hyperferritinemia in reactive hemophagocytic syndrome report of four adult cases. Am J Hematol 1995; 49:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/48\">",
"      Gupta S, Imam A, Licorish K. Serum ferritin in acquired immune deficiency syndrome. J Clin Lab Immunol 1986; 20:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/49\">",
"      McKenzie SW, Means RT Jr. Extreme hyperferritinemia in patients infected with human immunodeficiency virus is not a highly specific marker for disseminated histoplasmosis. Clin Infect Dis 1997; 24:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/50\">",
"      Ooi GC, Khong PL, Chan GC, et al. Magnetic resonance screening of iron status in transfusion-dependent beta-thalassaemia patients. Br J Haematol 2004; 124:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/51\">",
"      Gandon Y, Olivi&eacute; D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004; 363:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/52\">",
"      Al&uacute;stiza JM, Artetxe J, Castiella A, et al. MR quantification of hepatic iron concentration. Radiology 2004; 230:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/53\">",
"      St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/54\">",
"      Wood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation 2005; 112:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/55\">",
"      Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005; 106:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/56\">",
"      Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/57\">",
"      Hankins JS, McCarville MB, Loeffler RB, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 2009; 113:4853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/58\">",
"      Noetzli LJ, Coates TD, Wood JC. Pancreatic iron loading in chronically transfused sickle cell disease is lower than in thalassaemia major. Br J Haematol 2011; 152:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/59\">",
"      Wood JC, Mo A, Gera A, et al. Quantitative computed tomography assessment of transfusional iron overload. Br J Haematol 2011; 153:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/60\">",
"      Brittenham GM, Sheth S, Allen CJ, Farrell DE. Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. Semin Hematol 2001; 38:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/61\">",
"      Fischer R, Longo F, Nielsen P, et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003; 121:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/62\">",
"      Ludwig J, Batts KP, Moyer TP, et al. Liver biopsy diagnosis of homozygous hemochromatosis: a diagnostic algorithm. Mayo Clin Proc 1993; 68:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/63\">",
"      Kowdley KV, Trainer TD, Saltzman JR, et al. Utility of hepatic iron index in American patients with hereditary hemochromatosis: a multicenter study. Gastroenterology 1997; 113:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/64\">",
"      Bacon BR, Olynyk JK, Brunt EM, et al. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999; 130:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/65\">",
"      Bacon BR, Sadiq SA. Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am J Gastroenterol 1997; 92:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/66\">",
"      Barton JC, Preston BL, McDonnell SM, Rothenberg BE. Severity of iron overload in hemochromatosis: effect of volunteer blood donation before diagnosis. Transfusion 2001; 41:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/67\">",
"      Moirand R, Jouanolle AM, Brissot P, et al. Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives. Gastroenterology 1999; 116:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/68\">",
"      Franks AL, Burke W. Will the real hemochromatosis please stand up? Ann Intern Med 1999; 130:1018.",
"     </a>",
"    </li>",
"    <li>",
"     www.genetests.org (Accessed on December 04, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/70\">",
"      Bulaj ZJ, Griffen LM, Jorde LB, et al. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996; 335:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/71\">",
"      Finch CA, Huebers H. Perspectives in iron metabolism. N Engl J Med 1982; 306:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35129/abstract/72\">",
"      LeSage GD, Baldus WP, Fairbanks VF, et al. Hemochromatosis: genetic or alcohol-induced? Gastroenterology 1983; 84:1471.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7157 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-4D580CFE0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35129=[""].join("\n");
var outline_f34_19_35129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IRON TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Homozygous HH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Routine iron studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cutoff levels for screening purposes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2275080\">",
"      AASLD screening guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Sources of error",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14968470\">",
"      - High levels of ferritin in the absence of iron overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2234669\">",
"      Extremely high levels of ferritin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CT, MRI, and SQUID techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Patients who may not need a liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Response to phlebotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Genetic testing for HH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Iron status in HH heterozygotes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Distinction from alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2563985\">",
"      Causes of iron overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2563874\">",
"      Suspecting iron overload from iron studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2564098\">",
"      Suspecting iron overload from serial phlebotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7157\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7157|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?6/49/6943\" title=\"algorithm 1\">",
"      Testing and treatment for HH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7157|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/31/36337\" title=\"diagnostic image 1\">",
"      Hemochromatosis of liver CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/45/2769\" title=\"diagnostic image 2\">",
"      Hemochromatosis MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7157|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/44/42701\" title=\"figure 1\">",
"      Iron stores thalassemia major",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7157|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/40/18056\" title=\"picture 1A\">",
"      Iron overload liver Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/53/3927\" title=\"picture 1B\">",
"      Iron overload liver Perls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7157|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/43/17084\" title=\"table 1\">",
"      Causes secondary iron overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/52/16204\" title=\"table 2\">",
"      Accuracy transferrin saturation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/13/2266?source=related_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33748?source=related_link\">",
"      Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/36/43591?source=related_link\">",
"      Long-term management of the thalassemic patient after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35543?source=related_link\">",
"      Mean corpuscular volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=related_link\">",
"      Pathophysiology of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/15/40179?source=related_link\">",
"      Patient information: Hemochromatosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/41/2709?source=related_link\">",
"      Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28458?source=related_link\">",
"      Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12535?source=related_link\">",
"      Screening for hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18952?source=related_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_19_35130="Diagnosis of multiple sclerosis in adults";
var content_f34_19_35130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of multiple sclerosis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/19/35130/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/19/35130/contributors\">",
"     Michael J Olek, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/19/35130/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/19/35130/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/19/35130/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/19/35130/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/19/35130/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple sclerosis (MS) is the most common autoimmune inflammatory demyelinating disease of the central nervous system. This disease primarily affects women of Northern European descent who are of child-bearing age. MS is characterized pathologically by multifocal areas of demyelination with loss of oligodendrocytes and astroglial scarring. Axonal injury is increasingly recognized as a prominent pathologic feature of MS.",
"   </p>",
"   <p>",
"    Certain clinical features are typical of MS, but the disease has a highly variable pace and many atypical forms. Investigative studies such as MRI, evoked potentials, and spinal fluid analysis are often needed to confirm the diagnosis and exclude other possibilities.",
"   </p>",
"   <p>",
"    The diagnosis, differential diagnosis, and unusual presentations of MS are reviewed here. Other aspects of MS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41082?source=see_link\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26265?source=see_link\">",
"     \"Treatment of progressive multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36985?source=see_link\">",
"     \"Comorbid problems associated with multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple sclerosis (MS) is a clinical diagnosis. The clinical manifestations of MS are reviewed here briefly and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\", section on 'Clinical symptoms and signs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no clinical findings that are unique to this MS, but some are highly characteristic (",
"    <a class=\"graphic graphic_table graphicRef63940 \" href=\"mobipreview.htm?21/53/22363\">",
"     table 1",
"    </a>",
"    ). Common symptoms of MS are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef61789 \" href=\"mobipreview.htm?33/55/34684\">",
"     table 2",
"    </a>",
"    ). The typical patient presents as a young adult with two or more clinically distinct episodes of central nervous system dysfunction with at least partial resolution. Presenting symptoms and signs may be either monofocal (consistent with a single lesion) or multifocal (consistent with more than one lesion). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=see_link\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The history and physical examination are most important for diagnostic purposes, although a number of laboratory tests support the diagnosis (",
"    <a class=\"graphic graphic_table graphicRef76227 \" href=\"mobipreview.htm?20/46/21227\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Diagnostic criteria for MS developed in the early 1980s (the Poser criteria) considered clinical characteristics and a number of laboratory studies including cerebrospinal fluid analysis, evoked potentials, and neuroimaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/1\">",
"     1",
"    </a>",
"    ]. These findings were then used to place patients in categories ranging from clinically definite to laboratory supported definite to clinically probable to laboratory supported probable MS. The Poser criteria were developed primarily to ensure that only MS patients were included in research studies. They have been supplanted by the McDonald criteria, which were developed in 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/2\">",
"     2",
"    </a>",
"    ] and subsequently revised in 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/3\">",
"     3",
"    </a>",
"    ] and 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     McDonald criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The McDonald criteria, first developed in 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/2\">",
"     2",
"    </a>",
"    ] and revised in 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/3\">",
"     3",
"    </a>",
"    ], were revised again in 2010 in order to incorporate newer evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/5-7\">",
"     5-7",
"    </a>",
"    ] and to simplify the use of neuroimaging while preserving the sensitivity and specificity of the criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/4\">",
"     4",
"    </a>",
"    ]. The core requirement of the diagnosis is the objective demonstration of dissemination of central nervous system (CNS) lesions in both space and time, based upon either clinical findings alone or a combination of clinical and MRI findings (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Magnetic resonance imaging'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dissemination in space",
"      </strong>",
"      is demonstrated on MRI by one or more T2 lesions in at least two of four MS-typical regions of the CNS (periventricular, juxtacortical, infratentorial, or spinal cord)",
"      <strong>",
"       or",
"      </strong>",
"      by the development of a further clinical attack implicating a different central nervous system site. For patients with brainstem or spinal cord syndromes, symptomatic MRI lesions are excluded from the criteria and do not contribute to lesion count.",
"     </li>",
"     <li>",
"      <strong>",
"       Dissemination in time",
"      </strong>",
"      is demonstrated on MRI by the simultaneous presence of asymptomatic gadolinium-enhancing and nonenhancing lesions at any time, or a new T2",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of its timing with reference to a baseline scan,",
"      <strong>",
"       or",
"      </strong>",
"      by the development of a second clinical attack.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The McDonald criteria can only be applied after careful clinical evaluation of the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/4\">",
"     4",
"    </a>",
"    ]. The amount of additional data needed to confirm the diagnosis of MS depends upon the clinical presentation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with two or more attacks who have objective clinical evidence of two or more lesions or objective clinical evidence of one lesion with reasonable historical evidence of a prior attack, no additional data are required. However, it is desirable to make the diagnosis of MS with access to imaging. If MRI or other tests (eg, cerebrospinal fluid) are negative, alternative diagnoses must be considered. There must be no better explanation for the clinical presentation, and objective evidence must be present to support a diagnosis of MS.",
"     </li>",
"     <li>",
"      For patients with two or more attacks who have objective clinical evidence of one lesion, the criteria require evidence of",
"      <strong>",
"       dissemination in space",
"      </strong>",
"      .",
"     </li>",
"     <li>",
"      For patients with one attack who have objective clinical evidence of two or more lesions, the criteria require evidence of",
"      <strong>",
"       dissemination in time",
"      </strong>",
"      .",
"     </li>",
"     <li>",
"      For patients with one attack who have objective clinical evidence of one lesion (ie, a clinically isolated syndrome), the criteria require evidence of",
"      <strong>",
"       dissemination in space and time",
"      </strong>",
"      .",
"     </li>",
"     <li>",
"      For patients who present with insidious neurological progression suggestive of primary progressive MS, the criteria require evidence of the one year of disease progression (retrospectively or prospectively determined) plus two of the three following criteria (for patients with brainstem or spinal cord syndromes, symptomatic MRI lesions are excluded from the criteria and do not contribute to lesion count):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dissemination in space",
"      <strong>",
"       in the brain",
"      </strong>",
"      based upon one or more T2 lesions in at least two of four MS-typical regions of the central nervous system (periventricular, juxtacortical, infratentorial, or spinal cord)",
"     </li>",
"     <li>",
"      Dissemination in space",
"      <strong>",
"       in the spinal cord",
"      </strong>",
"      based upon two or more T2 lesions in the cord",
"     </li>",
"     <li>",
"      Positive cerebrospinal fluid findings with isoelectric focusing evidence of oligoclonal bands",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elevated IgG index",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An MS attack (also called a relapse or exacerbation) is defined by the McDonald criteria as patient-reported or objectively observed event typical of an acute inflammatory demyelinating event in the CNS, and can be either current or historical, with duration of at least 24 hours, in the absence of fever or infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/4\">",
"     4",
"    </a>",
"    ]. The attack should be confirmed by a neurologic examination, but some historical events with symptoms and evolution characteristic for MS, but for which no objective neurologic findings are documented, can provide reasonable evidence of a prior demyelinating event. Paroxysmal symptoms should consist of multiple episodes occurring over a minimum of 24 hours. Before a definite diagnosis of MS can be made, at least one attack must be confirmed by findings on either neurologic examination, visual evoked potential response in patients with prior visual disturbance, or MRI consistent with demyelination in CNS region associated with the prior neurologic symptoms.",
"   </p>",
"   <p>",
"    The McDonald criteria assign diagnostic confidence as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The diagnosis of \"MS\" is given if the criteria are fulfilled and there is no better explanation for the clinical presentation",
"     </li>",
"     <li>",
"      The diagnosis of \"possible MS\" is given if MS is suspected but the criteria are not completely met",
"     </li>",
"     <li>",
"      The diagnosis of \"not MS\" is given if another diagnosis better explains the clinical presentation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is not clear if the McDonald criteria are sufficiently accurate in patients with a clinically isolated syndrome to make decisions regarding disease modifying therapy. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37112?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinically isolated syndromes suggestive of multiple sclerosis\", section on 'McDonald diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is the test of choice to support the clinical diagnosis of MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/8\">",
"     8",
"    </a>",
"    ]. The McDonald diagnostic criteria for MS include specific MRI criteria for the demonstration of lesion dissemination in time and space as discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Lesion characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic lesion demonstrated on MRI is the cerebral or spinal plaque. Pathologically, plaques consist of a discrete region of demyelination with relative preservation of axons. However, mounting evidence suggests that axonal injury is a prominent pathologic feature of MS, and that axonal loss may occur either as part of the demyelinating process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/9\">",
"     9",
"    </a>",
"    ], or as an independent process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/10\">",
"     10",
"    </a>",
"    ]. Histological examination of active plaques reveals perivascular infiltration of lymphocytes (predominantly T cells) and macrophages with occasional plasma cells. Perivascular and interstitial edema may be prominent.",
"   </p>",
"   <p>",
"    Plaques suggestive of MS are typically found on MRI in the periventricular region, corpus callosum, centrum semiovale, and, to a lesser extent, deep white matter structures and basal ganglia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61864 \" href=\"mobipreview.htm?38/38/39526\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73197 \" href=\"mobipreview.htm?12/9/12439\">",
"     image 2",
"    </a>",
"    ). MS plaques usually have an ovoid appearance, and lesions are arranged at right angles to the corpus callosum as if radiating from this area. The plaques appear hyperintense on proton density and T2-weighted studies, and they are hypointense (if visible at all) on T1-weighted images.",
"   </p>",
"   <p>",
"    Conventional T2-weighted MRI techniques may underestimate MS plaque size and thus overall plaque burden. Advanced MRI techniques such as diffusion tensor imaging and magnetic resonance spectroscopy frequently reveal involvement of normal appearing white matter in patients with MS. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Advances in MRI techniques'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Diagnostic utility",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI detects many more MS lesions than CT, and it is able to detect plaques in regions that are rarely abnormal on CT such as the brainstem, cerebellum, and spinal cord (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73197 \" href=\"mobipreview.htm?12/9/12439\">",
"     image 2",
"    </a>",
"    ). Most lesions seen on MRI correlate with pathologic lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/11\">",
"     11",
"    </a>",
"    ]. However, some lesions that are extensive on MRI show only small plaques on pathological examination, suggesting that much of the abnormal MRI signal may be a result of increased water content of the brain around such plaques due to presumed disruption of the blood-brain barrier.",
"   </p>",
"   <p>",
"    Patients with clinically definite MS have typical white matter lesions on MRI in over 90 percent of cases. However, central nervous system lesions due to other disorders (eg, ischemia, systemic lupus erythematosus, Beh&ccedil;et&rsquo;s disease, other vasculitides, HTLV-I, sarcoidosis) may appear similar to MS lesions on MRI. This is particularly true for ischemic lesions, which make MRI criteria less reliable for the diagnosis of MS in patients over the age of 50 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity and specificity of MRI for the diagnosis of MS varies widely in different studies, and the variation is probably due to differences among the studies in MRI criteria and patient populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/13\">",
"     13",
"    </a>",
"    ]. In one early study of 1500 brain MRI scans that included 134 scans of patients with a clinical diagnosis of MS, using the criteria of three or four areas of increased signal intensity resulted in a high sensitivity for the diagnosis of MS (90 and 87 percent, respectively), but a low specificity (71 and 74 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/12\">",
"     12",
"    </a>",
"    ]. Accuracy was improved with criteria that included at least three areas of increased signal intensity plus two of the following features: lesions abutting body of lateral ventricles; infratentorial lesion location; and size &gt;5 mm. Using these criteria, sensitivity decreased slightly to 81 percent while specificity improved to 96 percent. In a later study evaluating MRI diagnostic criteria that were eventually incorporated into the revised 2010 McDonald criteria, the sensitivity and specificity were approximately 53 and 87 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI scanning is more sensitive and specific for predicting evolution to clinically definite MS than other studies such as CT scans, cerebrospinal fluid parameters, or evoked potentials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/14\">",
"     14",
"    </a>",
"    ]. This was illustrated in a two-year follow-up of 200 patients referred for suspected MS that found 30 percent (50 percent of those under age 50 years) had developed clinically definite MS, of whom 84 percent had initial MRI scans that were strongly suggestive of MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/15\">",
"     15",
"    </a>",
"    ]. In contrast, the proportion of patients who had cerebrospinal fluid oligoclonal bands, abnormal visual evoked potentials, or an abnormal CT when initially studied was 69, 69, and 38 percent, respectively. In a second, five-year study of 89 patients, progression to clinically definite MS occurred in 37 out of 57 (65 percent) with an initially abnormal MRI, and only 1 of 32 (3 percent) with a normal MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/16\">",
"     16",
"    </a>",
"    ]. Again, MRI was a better predictor of progression to clinically definite MS than cerebrospinal fluid analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Spinal cord MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of abnormal signals on spinal cord MRI in normal individuals is only 3 percent, since the non-MS-related hyperintense signal seen in older patients on cranial MRI does not occur in the spinal cord. In contrast, spinal cord MRI lesions are nearly as common as brain MRI lesions in MS patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spinal cord MRI may increase the likelihood of finding dissemination of MS lesions in space and improve diagnostic sensitivity compared with brain MRI alone. The potential utility of spinal MRI in MS is illustrated by a study of 104 patients with early stage MS and low disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/18\">",
"     18",
"    </a>",
"    ]. The diagnosis of MS was made by the 1982 criteria of Poser et al [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/1\">",
"     1",
"    </a>",
"    ]. Abnormal cord MRI lesions were found in 83 percent, and these lesions were typically focal; focal cord lesions were usually multiple (median 3), small (median 0.8 vertebral segments), and located most often in the cervical cord (56 percent). Diffuse lesions were found in 13 percent, usually in conjunction with focal lesions. In this cohort of patients, the addition of spinal cord to brain MRI lesions, compared with brain MRI alone, increased the diagnostic sensitivity of the original 2001 McDonald criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/2\">",
"     2",
"    </a>",
"    ] from 66 to 85 percent.",
"   </p>",
"   <p>",
"    Spinal cord lesions typical of MS are associated with the following MRI characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/3,18-20\">",
"     3,18-20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Little or no cord swelling",
"     </li>",
"     <li>",
"      Unequivocal hyperintensity on T2-weighted sequences",
"     </li>",
"     <li>",
"      Size at least 3 mm but less than two vertebral segments in length",
"     </li>",
"     <li>",
"      Occupy only part of the cord in cross-section",
"     </li>",
"     <li>",
"      Focal (ie, clearly delineated and circumscribed on T2-weighted sequences)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Longitudinally extensive spinal cord lesions, particularly those that exceed three spinal segments and mainly involve the central cord on axial MRI sections, are suggestive of neuromyelitis optica [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Neuromyelitis optica and optic-spinal MS'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Active versus chronic lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts continue to delineate differences in the MRI appearance of acute or active lesions and chronic lesions. Acute lesions tend to be larger with somewhat ill-defined margins and become smaller with sharper margins as resolution occurs. This presumably reflects resolution of edema and inflammation present at the time of acute plaque formation, leaving only residual areas of demyelination, gliosis, and enlarged extracellular space with remission. The MRI appearance of primary progressive MS shows a smaller total disease burden, a greater preponderance of small lesions, fewer gadolinium enhancing new lesions, and acquisition of fewer lesions per unit time than the secondary progressive form of MS.",
"   </p>",
"   <p>",
"    Gadolinium-DTPA, a paramagnetic contrast agent that can cross only disrupted blood-brain barrier, has been used to assess plaque activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/21\">",
"     21",
"    </a>",
"    ]. Gadolinium increases signal intensity on T1-weighted images. It is not completely clear if inflammation is the triggering event that causes demyelination and axonal degeneration, but gadolinium enhancement diminishes or disappears after treatment with glucocorticoids, a therapy thought to restore integrity of the blood-brain barrier.",
"   </p>",
"   <p>",
"    Gadolinium (Gd) enhancing lesions on T1-weighted MRI often correspond to areas of high signal on T2-weighted and low signal intensity on unenhanced T1-weighted images, probably due to edema (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61864 \" href=\"mobipreview.htm?38/38/39526\">",
"     image 1",
"    </a>",
"    ). The importance of Gd-enhancing lesions in MS is related to the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The accumulation of gadolinium in plaques is associated with new or newly active plaques and with pathologically confirmed acute inflammation in MS.",
"     </li>",
"     <li>",
"      The majority of Gd-enhancing plaques are clinically asymptomatic, although the presence of ongoing enhancement suggests continuing disease activity that likely contributes to cumulative pathophysiology.",
"     </li>",
"     <li>",
"      Approximately 10 to 20 percent of lesions on T2-weighted MRI will show contrast enhancement at any one time.",
"     </li>",
"     <li>",
"      Gadolinium enhancement is a transient phenomenon in MS and usually disappears after 30 to 40 days, but it may rarely persist for up to eight weeks in acute plaques. Prolonged persistence of enhancement should caution against the diagnosis of MS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Longitudinal studies have demonstrated that the presence of active lesions on serial MRI scans carries a high risk of continuous disease activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis demonstrated that Gd enhancement predicts the occurrence of relapses, but it is not a strong predictor of the development of cumulative impairment or disability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several methods that can be used to increase the sensitivity of Gd-enhanced MRI for the detection of active MS lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/26\">",
"     26",
"    </a>",
"    ], such as using higher doses of Gd [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In particular, triple-dose Gd is more sensitive than single-dose Gd (0.1",
"    <span class=\"nowrap\">",
"     mmol/kg)",
"    </span>",
"    in detecting MS lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/29\">",
"     29",
"    </a>",
"    ]. Other useful techniques for increasing sensitivity include thinner slices or delayed imaging. Newer methods such as magnetization transfer contrast imaging (MTI) also increase sensitivity of Gd [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gadolinium enhancement patterns may provide some clues to the underlying pathology of lesions. Concentric ring-enhancing lesions with central contrast pallor arise in previously damaged areas or in areas of accelerated local inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/31-38\">",
"     31-38",
"    </a>",
"    ]. They are larger and of longer duration than homogeneously-enhancing lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/32,33,35\">",
"     32,33,35",
"    </a>",
"    ]. Moreover, ring-enhancing lesions weakly predict the development of persisting hypointense lesions on T1 MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Black holes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Therefore, ring-enhancing lesions are thought to be related to accelerated disease activity and extensive tissue damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/32,38,39\">",
"     32,38,39",
"    </a>",
"    ] and may mark a type of inflammation characteristic of more aggressive forms of disease. Ring enhancement may also occur in an incomplete (open) ring pattern, which is somewhat more specific for MS than infections or neoplastic diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Black holes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most MS lesions are isointense to white matter on T1-weighted MRI, but some are hypointense or appear as \"black holes\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/40-43\">",
"     40-43",
"    </a>",
"    ], particularly in the supratentorial region (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61864 \" href=\"mobipreview.htm?38/38/39526\">",
"     image 1",
"    </a>",
"    ). These hypointense lesions are nonspecific at a given time point, as nearly half will revert to normal in a few months. The disappearance of a black hole is most likely due to remyelination and resolution of edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the evidence is limited, persistent black holes are thought to be markers of severe demyelination and axonal loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/40\">",
"     40",
"    </a>",
"    ]. The pathological substrate for the accumulation of persisting black holes appears to be predominantly axonal damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/40,41,44\">",
"     40,41,44",
"    </a>",
"    ], as shown in a postmortem histopathology-MRI correlation study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/40\">",
"     40",
"    </a>",
"    ]. Such focal axonal loss most likely contributes to Wallerian degeneration. In contrast to this evidence, another study suggested that black holes were associated with remyelination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The correlation between black hole volume and clinical disability, as measured by the Expanded Disability Status Scale (EDSS), suggests that these black holes may be clinically relevant for measuring disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is evidence that disease-modifying therapies for MS including beta interferons and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    can reduce the formation of black holes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/46-51\">",
"     46-51",
"    </a>",
"    ], although it is unclear if currently available agents can enhance the resolution of black holes once they have formed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Advances in MRI techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to distinguish the edema of an acute plaque from the gliosis and demyelination of a chronic plaque with conventional MRI technology. In addition, conventional MRI techniques do not distinguish other manifestations of MS pathology such as demyelination, remyelination, axonal loss, and gliosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phosphorus magnetic resonance spectroscopy (MRS) can provide information on phospholipid metabolism, and proton MRS can generate information about other metabolic components, such as N-acetyl aspartate (NAA, an exclusively neuronal marker), creatine phosphate (Cr, an energy marker), choline containing compounds (membrane components), and lactic acid (LA). Chronic MS is associated with a reduction of NAA in comparison to C and Cr within the brain. A reduced",
"    <span class=\"nowrap\">",
"     NAA/Cr",
"    </span>",
"    ratio is the common means of expressing such reduction. This reduced ratio implies loss of neurons or axons, which is consistent with pathological studies and appears to parallel disability in MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/54\">",
"     54",
"    </a>",
"    ]. In addition, the whole-brain concentration of NAA may be a sensitive surrogate marker of neuronal loss in MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diffusion-weighted and diffusion tensor MRI imaging as well as MRS may provide insight into the axonal loss and diffuse abnormalities in normal appearing white matter and the evolution of normal appearing gray matter that can occur MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Quantitative MRI methods such as magnetization transfer ratio are increasingly used to assess myelin content and axonal count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diffusion tensor imaging allows measurement of fractional anisotropy, which reflects the degree to which the diffusion of water molecules follows one direction versus many directions. This technique is useful for assessing the integrity of white matter tracts, which normally have a high degree of anisotropy due to their linear arrangement and the preferred diffusion of water along the long axis of the myelinated fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/61\">",
"     61",
"    </a>",
"    ]. Injury to nerve axons or myelin sheaths permits increased diffusion of water across the white matter tract and thereby decreases fractional anisotropy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52184 \" href=\"mobipreview.htm?14/44/15044\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Normal appearing white matter that is immediately adjacent to plaques seen on T2 imaging may have abnormally reduced anisotropy. As an example, a study that evaluated 36 white matter plaques in 20 patients with MS found that mean plaque size, as measured by a 40 percent reduction in fractional anisotropy, was significantly increased (145 percent) compared with the size measured by conventional T2-weighted imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathologic correlate of the decreased fractional anisotropy in white matter that appears normal on T2-weighted MRI is uncertain. One possibility is that demyelination and axonal disruption at the periphery of a centrifugally expanding plaque is less severe than at the center; the peripheral injury is sufficient to cause reduced anisotropy but not sufficient to cause increased T2 signal. Another possibility is that the periphery is undergoing regression and repair.",
"   </p>",
"   <p>",
"    Although MS predominately affects white matter, involvement of cortical gray matter is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. Visualization of gray matter lesions may be improved with the use of MRI techniques, including two and three-dimensional fluid-attenuated inversion recovery imaging, double inversion recovery imaging, phase-sensitive inversion recovery T1-weighted sequences, and diffusion tensor imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/63,66-72\">",
"     63,66-72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cerebrospinal fluid analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Qualitative assessment of cerebrospinal fluid (CSF) for oligoclonal IgG bands (OCBs) using isoelectric focusing is the most important diagnostic CSF study when determining a diagnosis of MS. Elevation of the CSF immunoglobulin level relative to other protein components is a common finding in patients with MS and suggests intrathecal synthesis. The immunoglobulin increase is predominantly IgG, although the synthesis of IgM and IgA is also increased.",
"   </p>",
"   <p>",
"    The 2010 McDonald criteria note that positive CSF findings can provide supportive evidence that the underlying disorder is inflammatory demyelinating, and incorporate them into the criteria for primary progressive MS. However, in contrast to the earlier 2001 and 2005 McDonald criteria, the CSF findings are",
"    <strong>",
"     not",
"    </strong>",
"    incorporated into the 2010 criteria for dissemination in space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A positive CSF is based upon the finding of either OCBs different from any such bands in serum, or by an increased IgG index. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Oligoclonal bands'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13\">",
"     'Expert recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The IgG level may be expressed as a percentage of total protein (normal &lt;11 percent), as a percentage of albumin (normal &lt;27 percent), by use of the IgG index (normal value &lt;0.66 to &lt;0.9, depending upon the individual laboratory), or by use of a formula for intrathecal fluid synthesis of IgG. An abnormality of CSF IgG production as measured by the IgG index or IgG synthesis rate is found in 90 percent of clinically definite MS patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CSF is grossly normal in MS, and CSF pressure is normal. The total leukocyte count is normal in two-thirds of patients, exceeds 15",
"    <span class=\"nowrap\">",
"     cells/&micro;L",
"    </span>",
"    in &lt;5 percent, and only rarely exceeds 50",
"    <span class=\"nowrap\">",
"     cells/&micro;L",
"    </span>",
"    (a finding that should raise suspicion of another etiology) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/74\">",
"     74",
"    </a>",
"    ]. Lymphocytes are the predominant cell type, the vast majority of which are T cells. CSF protein (or albumin) level is usually normal. Albumin is not synthesized in the central nervous system, and albumin determination therefore gives a better indication of blood-CSF-barrier disruption than does total protein, some of which may be synthesized within the central nervous system (eg, immunoglobulin).",
"   </p>",
"   <p>",
"    The technique for performing a lumbar puncture in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/6/19561?source=see_link\">",
"     \"Lumbar puncture: Technique; indications; contraindications; and complications in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/10/17576?source=see_link&amp;anchor=H8#H8\">",
"     \"Cerebrospinal fluid: Physiology and utility of an examination in disease states\", section on 'Composition of the CSF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Oligoclonal bands",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oligoclonal bands (OCBs) are found in &ge;95 percent of patients with clinically definite MS (",
"    <a class=\"graphic graphic_table graphicRef76227 \" href=\"mobipreview.htm?20/46/21227\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/75\">",
"     75",
"    </a>",
"    ]. These represent limited classes of antibodies that are depicted as discrete bands on agarose gel. Up to 8 percent of cerebrospinal fluid (CSF) samples from patients without MS also contain OCBs; most are the result of chronic central nervous system infections, viral syndromes, and neuropathies.",
"   </p>",
"   <p>",
"    The presence of OCBs in monosymptomatic patients predicts a significantly higher rate of progression to MS than the absence of bands: 25 versus 9 percent at three years follow-up in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/73\">",
"     73",
"    </a>",
"    ]. However, quantification of OCBs is an insensitive prognostic indicator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/76\">",
"     76",
"    </a>",
"    ]. In addition, the presence of OCBs is",
"    <strong>",
"     not",
"    </strong>",
"    equivalent to a diagnosis of MS, given the number of false positives that can occur and the variability in technique and interpretation in different laboratories.",
"   </p>",
"   <p>",
"    There are five classic patterns of OCBs seen using isoelectric focusing on agarose gels with immunoblotting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/75\">",
"     75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 - No OCBs in CSF and serum samples",
"     </li>",
"     <li>",
"      Type 2 - OCBs in CSF but not serum, indicating intrathecal IgG synthesis",
"     </li>",
"     <li>",
"      Type 3 - OCBs in CSF with additional identical OCBs in CSF and serum but still indicating intrathecal IgG synthesis",
"     </li>",
"     <li>",
"      Type 4 - Identical OCBs in CSF and serum, indicating a systemic immune reaction with a normal or abnormal blood-CSF barrier and passive transfer of OCBs to the CSF",
"     </li>",
"     <li>",
"      Type 5 - Monoclonal bands in CSF and serum, indicating the presence of a monoclonal gammopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Expert recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted earlier, a panel of experts issued recommendations in 2005 for the evaluation of CSF in patients suspected of having MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/75\">",
"     75",
"    </a>",
"    ]. These expert recommendations are aimed particularly at neurologists and laboratory medicine specialists.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The single most informative \"gold standard\" analysis is qualitative assessment of CSF for IgG oligoclonal bands; this is best performed using isoelectric focusing on agarose gels followed by immunodetection by blotting or fixation. This method achieves the greatest sensitivity and specificity for a diagnosis of MS.",
"     </li>",
"     <li>",
"      Repeating the lumbar puncture and CSF analysis is suggested if clinical suspicion for MS is high but results are equivocal, negative, or show only a single band on isoelectric focusing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Evoked potentials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evoked potentials (EPs) are the electrical events generated in the central nervous system by peripheral stimulation of a sensory organ. EPs are used to detect abnormal central nervous system function that may be clinically undetectable. Detection of a subclinical lesion in a site remote from the region of clinical dysfunction supports a diagnosis of multifocal MS. EPs also may help define the anatomical site of the lesion in tracts not easily visualized by imaging (eg, optic nerves, dorsal columns).",
"   </p>",
"   <p>",
"    The three most frequently used EPs are somatosensory (SSEP), visual (VER), and brainstem auditory evoked potentials (BAEP).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with clinically definite MS have abnormal VERs in 85 percent of cases (",
"      <a class=\"graphic graphic_table graphicRef76227 \" href=\"mobipreview.htm?20/46/21227\">",
"       table 3",
"      </a>",
"      ). The VER is particularly useful in patients who lack clear clinical evidence of dysfunction above the level of the foramen magnum, such as those with a chronic progressive myelopathy. Ocular or retinal disorders must be excluded before attributing abnormal VERs to demyelination in the optic pathways.",
"     </li>",
"     <li>",
"      SSEPs are abnormal in 77 percent of patients with MS, including approximately one-half of those who do not have sensory signs or symptoms. Some patients with clinical evidence of posterior column dysfunction may have normal SSEPs.",
"     </li>",
"     <li>",
"      BAEP abnormalities are less frequent in MS than VER or SSEP abnormalities, being present in 67 percent of patients with MS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Consistent with these findings, guidelines from the American Academy of Neurology (AAN) state that VERs are probably useful for identifying patients with clinically definite MS, SSEPs are possibly useful, and there is insufficient evidence at this time to recommend BAEP as a useful test for diagnostic purposes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinically isolated syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically isolated syndromes are single, monosymptomatic attacks compatible with MS (eg, optic neuritis) that can create a diagnostic, and therefore therapeutic, dilemma. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37112?source=see_link\">",
"     \"Clinically isolated syndromes suggestive of multiple sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antimyelin antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies suggested that antibodies to myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) were potential markers of MS disease activity and predictors of progression from a CIS to MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. However, subsequent evidence suggests that these antibodies are not associated with an increased risk of progression from a CIS to MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/80-82\">",
"     80-82",
"    </a>",
"    ] or with MS disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors may contribute to the discrepant findings, such as differences in technique used in MOG preparation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/79,83,84\">",
"     79,83,84",
"    </a>",
"    ]. In addition, autoantibodies to many myelin constituents in patients with MS, including anti-MOG, may simply represent part of a generalized \"nonsense\" antibody response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/85\">",
"     85",
"    </a>",
"    ], reflecting an increased immune response due to MS rather than to a specific root cause of MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with neuromyelitis optica appear to have elevated numbers of anti-MOG secreting cells in cerebrospinal fluid. However, it remains to be established whether serum antimyelin antibodies have any clinical utility in distinguishing patients with MS from those with neuromyelitis optica. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Neuromyelitis optica and optic-spinal MS'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359983\">",
"    <span class=\"h1\">",
"     UNUSUAL CLINICAL PRESENTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several inflammatory demyelinating disorders bear an unknown relationship to MS. Some patients have their entire clinical illness confined to the optic nerves. One optic nerve may be affected sequentially after another, or there can be simultaneous bilateral visual loss, a state which is uncommon in classic MS. In some instances, head MRI will show scattered intracerebral lesions in addition to lesions of the optic nerves, or cerebrospinal fluid examination will show oligoclonal bands, attesting to some degree of dissemination of the lesions. Children and preadolescent patients are more likely than adults to have recurrent or simultaneous optic neuropathy. The distinction from an MS variant can be challenging. Sarcoidosis is commonly a diagnostic consideration in patients with bilateral optic neuritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359990\">",
"    <span class=\"h2\">",
"     Progressive spinal cord syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A syndrome of slowly progressive spinal cord dysfunction can present a major diagnostic challenge. As an example, one case series described seven patients who developed a progressive myelopathy with motor impairment attributable to a single demyelinating lesion on MRI in the upper cervical spinal cord or brainstem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/86\">",
"     86",
"    </a>",
"    ]. None had clinical symptoms suggestive of relapses affecting other portions of the central nervous system, and no new lesions were found in the three patients who had serial MRI scans of the brain and spinal cord. Oligoclonal bands were present in four of the six patients tested. There was no evidence suggesting another etiology for progressive myelopathy, such as neuromyelitis optica.",
"   </p>",
"   <p>",
"    The differential diagnosis of progressive myelopathy includes inflammatory, infectious, paraneoplastic and metabolic disorders. Motor neuron disease may be the cause if there are no sensory signs or symptoms (primary lateral sclerosis). HTLV-I infection, B12 deficiency, and HIV infection can all be excluded by appropriate testing. Spinal dural arteriovenous malformation can cause a steadily or stepwise progressive myelopathy, usually in the lower spinal segments. Adrenomyeloneuropathy also should be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=see_link\">",
"     \"Disorders affecting the spinal cord\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16938?source=see_link\">",
"     \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40808?source=see_link\">",
"     \"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=see_link\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22808?source=see_link\">",
"     \"Acute and early HIV infection: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=see_link&amp;anchor=H17#H17\">",
"     \"Disorders affecting the spinal cord\", section on 'Vascular malformations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33673?source=see_link&amp;anchor=H8#H8\">",
"     \"Adrenoleukodystrophy\", section on 'Adrenomyeloneuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Eventually there remains a group of patients who do not fit into these categories and whose spinal MRI scans are repeatedly negative. Visual evoked responses, cerebrospinal fluid oligoclonal bands, and head MRI scan show no sign of demyelination elsewhere. No firm diagnosis is possible in these individuals. Minor clues that MS is present may be the presence of a Lhermitte sign (a term for electric shock-like sensations that run down the back",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    limbs upon flexion of the neck) that has come and gone or by undue sensitivity to elevated temperature. The degree of compression of the cervical cord by intervertebral disc disease is often an issue in the middle-aged patient, since a majority has some degree of disc disease. There is little doubt that some laminectomies have been carried out for cervical spondylosis where MS was the final correct diagnosis.",
"   </p>",
"   <p>",
"    Progressive myelopathy due to MS is part of the primary progressive MS group and carries the poor prognosis typical of that group. Choice of therapy is difficult. Some patients do better for a time with monthly IV glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359997\">",
"    <span class=\"h2\">",
"     Tumefactive multiple sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute tumor-like MS variant has been described in which some patients with demyelinating disease present with large (&gt;2 cm) acute lesions, often associated with edema or ring enhancement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. There may be mass effect, with compression of the lateral ventricle and shift across the midline. Although there is no consensus regarding nomenclature, this type of inflammatory demyelinating disease has been termed tumefactive multiple sclerosis, pseudotumoral multiple sclerosis, transitional sclerosis, diffuse myelinoclastic sclerosis, Marburg disease or variant, and Balo concentric sclerosis.",
"   </p>",
"   <p>",
"    The clinical abnormalities in such patients are variable; they may be very slight even in a patient with a massive lesion, while confusion, hemiparesis, or neglect syndrome can be seen in another patient with a lesion that appears no different. Typically, much of the T2-bright lesion volume on brain MRI is due to edema and may be rapidly responsive to glucocorticoid treatment. However, radiologic improvement with glucocorticoids can also occur with glioma or with central nervous system lymphoma and is therefore not a useful diagnostic criterion. Biopsy is often required.",
"   </p>",
"   <p>",
"    In the largest series, 168 patients with biopsy-confirmed tumor-like inflammatory demyelinating disease were retrospectively analyzed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/88\">",
"     88",
"    </a>",
"    ]. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median age at onset was 37 years (range 8 to 69).",
"     </li>",
"     <li>",
"      Clinical presentations were typically polysymptomatic. Motor, cognitive, sensory, and cerebellar symptoms were the most frequent.",
"     </li>",
"     <li>",
"      Lesions on brain MRI were often multifocal, and the median size of the largest T2 lesion was 4 cm. Gadolinium enhancement on brain MRI was observed in more than half of the lesions; ring, heterogeneous, and homogeneous patterns were the most common.",
"     </li>",
"     <li>",
"      The clinical course at last follow-up was relapsing-remitting in approximately one-half of the patients and monophasic in about one-quarter. The final diagnosis was definite or probable multiple sclerosis in 79 percent and an isolated demyelinating syndrome in 14 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of MS is limited in the setting of a young adult who has had two or more clinically distinct episodes of central nervous system dysfunction with at least partial resolution. Diagnostic difficulties arise in patients who have atypical presentations, monophasic episodes, or progressive illness (",
"    <a class=\"graphic graphic_table graphicRef76753 \" href=\"mobipreview.htm?22/46/23276\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The unusual nature of some sensory symptoms and the difficulty patients experience in describing such symptoms may result in a misdiagnosis of hysteria.",
"     </li>",
"     <li>",
"      A monophasic illness with symptoms attributable to one site in the central nervous system creates a large differential that includes neoplasms, vascular events, or infections.",
"     </li>",
"     <li>",
"      The most trouble arises with progressive central nervous system dysfunction; great care must be taken in these patients to exclude treatable etiologies (compressive spinal cord lesions, arteriovenous malformations, cavernous angiomas, Arnold-Chiari malformation), infection (human T-lymphotropic virus type I, human immunodeficiency virus), or hereditary disorders (adult metachromatic leukodystrophy, adrenoleukodystrophy, spinocerebellar disorders).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A common error is to over-interpret multiple hyperintense lesions on MRI as equivalent to MS in the absence of clinical symptoms consistent with the diagnosis (",
"    <a class=\"graphic graphic_table graphicRef61789 \" href=\"mobipreview.htm?33/55/34684\">",
"     table 2",
"    </a>",
"    ). Central nervous system inflammatory or infectious diseases such as systemic lupus erythematosus, Sj&ouml;gren's disease, polyarteritis nodosa, Beh&ccedil;et&rsquo;s disease, syphilis, and retroviral diseases may all produce multifocal lesions with or without a relapsing-remitting course. Systemic lupus erythematosus can present as a recurrent neurologic syndrome before the systemic manifestations of this disease appear. Beh&ccedil;et&rsquo;s syndrome is characterized by orogenital ulcerations; multifocal neurologic findings occur in less than one-third of these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33978?source=see_link\">",
"     \"Neurologic manifestations of systemic lupus erythematosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/18/298?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The inherited vasculopathy known as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) can likewise produce a pattern of brain lesions on MRI that can mimic the pattern seen in patients with MS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/16/11530?source=see_link\">",
"     \"Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many physicians fail to pursue further diagnostic steps when a patient is labeled as MS. Features that should alert the clinician to the possibility of other diseases include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Family history of neurologic disease",
"     </li>",
"     <li>",
"      A well demarcated spinal level in the absence of disease above the foramen magnum",
"     </li>",
"     <li>",
"      Prominent back pain that persists",
"     </li>",
"     <li>",
"      Symptoms and signs that can be attributed to one anatomical site",
"     </li>",
"     <li>",
"      Patients who are over 60 years of age or less than 15 years at the onset of disease",
"     </li>",
"     <li>",
"      Progressive disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of these features excludes the diagnosis of MS. However, one should explore the possibility of other etiologies before accepting the diagnosis of MS, particularly in patients who have atypical clinical syndromes. This point is illustrated by the findings from a study of 281 new patient referrals to an outpatient university-based MS center for a first or second opinion as to whether the patient had MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/90\">",
"     90",
"    </a>",
"    ]. Probable or possible MS was confirmed in only 33 percent of the 281 patients, and none of the patients with confirmed MS had atypical manifestations of demyelination. A wide variety of alternative diagnoses were made, including other neurologic diseases, possible psychiatric disease, and no clear diagnosis (31.5, 22.5 and 12.5 percent, respectively). The retrospective nature of this study limits the strength of its findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Acute disseminated encephalomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute disseminated encephalomyelitis (ADEM) is classically described as a uniphasic syndrome occurring in association with an immunization or vaccination (postvaccination encephalomyelitis) or systemic viral infection (parainfectious encephalomyelitis). Pathologically, there is perivascular inflammation, edema, and demyelination within the central nervous system.",
"   </p>",
"   <p>",
"    Clinically patients present with the rapid development of focal or multifocal neurologic dysfunction. Prototypical illness arises after acute measles infection or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/55/16246?source=see_link\">",
"     rabies vaccine",
"    </a>",
"    administration. Uncertainty regarding the diagnosis occurs when patients with clinical features of ADEM occur in the background of viral infections or vaccine administration not significantly linked with the syndrome by epidemiological criteria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/52/25416?source=see_link\">",
"     \"Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurologic sequelae complicate 1 in 400 to 1 in 1000 cases of measles infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/91\">",
"     91",
"    </a>",
"    ]. Multiple subgroups of patients have been described, including those with diffuse cerebral features, focal or multifocal cerebral findings, cerebellar dysfunction, and spinal cord abnormalities; patients do not develop peripheral nerve damage or relapses of disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43192?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical presentation and diagnosis of measles\", section on 'Acute disseminated encephalomyelitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to measles, a wide array of other viral and bacterial infections have tentatively been associated with ADEM, including rubella, mumps, herpes zoster, herpes simplex, influenza, Epstein-Barr virus, coxsackievirus, Borrelia burgdorferi, Mycoplasma, and Leptospira. Acute encephalomyelitis occurring in the background of nonspecific viral illness is difficult to diagnose with certainty and to distinguish from episodes of MS.",
"   </p>",
"   <p>",
"    The occurrence of neuroparalytic accidents as a consequence of the Pasteur",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/55/16246?source=see_link\">",
"     rabies vaccine",
"    </a>",
"    prepared from spinal cords of rabbits inoculated with fixed rabies virus was recorded soon after introduction of the treatment: the incidence of encephalomyelitis associated with the original Pasteur rabies vaccine prepared in rabbit brain has been estimated at 1 per 3,000 to 35,000 vaccinations. Similar neurologic complications were observed as a consequence of the Jenner vaccine used for the prevention of smallpox. Postvaccination ADEM does not appear to be due to the direct cytopathic effects of the virus, but rather to immune-mediated mechanisms directed against specific components of the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ADEM also has been associated with other vaccines, including pertussis, rubella, diphtheria, and measles. The association between influenza vaccination, particularly the swine flu vaccine, and ADEM has been the subject of medicolegal controversy.",
"   </p>",
"   <p>",
"    ADEM has been reported after the administration of some drugs. These drugs include sulfonamides and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15141?source=see_link\">",
"     para-aminosalicylic acid",
"    </a>",
"    <span class=\"nowrap\">",
"     (PAS)/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"      streptomycin",
"     </a>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    All of these associations can only be substantiated by strong epidemiological evidence or by the development of a pathognomonic laboratory finding for ADEM. However, neither of these circumstances currently exists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features of the postvaccination and parainfectious syndromes are similar, with the exception that the postrabies vaccination complications frequently involve the peripheral nervous system as well as the central nervous system. Many patients with postrabies immunization illness have only mild clinical features of fever, headache, or myalgia without CSF pleocytosis.",
"   </p>",
"   <p>",
"    The hallmark clinical feature of the disorder is the development of a focal or multifocal neurologic disorder following exposure to virus or receipt of vaccine. In some, but not all cases, a prodromal phase of several days of fever, malaise, and myalgias occurs. The onset of the central nervous system disorder is usually rapid (abrupt or up to several hours), reaching peak dysfunction within several days. Initial features include encephalopathy ranging from lethargy to coma, seizures, and focal and multifocal signs reflecting cerebral (hemiparesis), brainstem (cranial nerve palsies), and spinal cord (paraparesis) involvement. Other reported findings include movement disorders and ataxia. Each of these findings may occur as isolated features or in various combinations.",
"   </p>",
"   <p>",
"    Features deemed characteristic of ADEM include simultaneous bilateral optic neuritis, loss of consciousness, meningismus, loss of deep tendon reflexes and retained abdominal reflexes in the presence of Babinski's reflexes, central body temperature of greater than 100&ordm;F (37.8&ordm;C), and severe shooting limb pains. By comparison, features characteristic of MS are unilateral optic neuritis, diplopia, hyperactive reflexes, and preserved awareness. Headache is an equivocal feature.",
"   </p>",
"   <p>",
"    Recovery can begin within days, with complete resolution noted on occasion within a few days, but more often over the course of weeks or months. Relapses are rare. Recovery from ADEM is more rapid compared with MS and usually more complete.",
"   </p>",
"   <p>",
"    The mortality rate varies among reported series but is usually estimated at 10 to 30 percent, with complete recovery rates of 50 percent cited. Poor prognosis is correlated with severity and abruptness of onset of the clinical syndrome. Measles virus-associated ADEM may carry a worse prognosis than vaccine-associated disease. In earlier series, the occurrence of acute hemiplegia, which was interpreted as vascular occlusions and akin to the syndrome of acute hemiplegia of childhood, carried a particularly unfavorable prognosis with respect to recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In ADEM, multifocal central nervous system lesions are generally evident on MRI and are initially indistinguishable from those observed in MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/93\">",
"     93",
"    </a>",
"    ]. Pathologically ADEM produces scattered small perivenous lesions, often uniform in size, but this feature is not reliably detected by MRI. After several weeks, ADEM lesions show at least partial resolution without the appearance of new lesions, unlike MS. In some cases lesions can persist. MRI in ADEM, as with MS, is more sensitive than CT scanning, which may in some cases show enhancing lesions.",
"   </p>",
"   <p>",
"    The usual cerebrospinal fluid (CSF) formula is normal pressure, little or no (&lt;100",
"    <span class=\"nowrap\">",
"     cells/&micro;L)",
"    </span>",
"    increase in cell count, and a modest increase in protein. Well-documented cases exist with totally normal CSF pressure, cell counts, and protein content. Cases with very high cell counts, including some polymorphonuclear cells and high protein values, appear to represent a more necrotizing disease process. The high counts usually return to normal within a few days. The CSF Ig content is not usually increased, and OCB patterns are not usually observed. The content of myelin basic protein (MBP) in the CSF may be increased, as it can be in many conditions in which myelin destruction occurs, as in MS, or as part of a more widespread tissue destructive process, like cerebral infarction.",
"   </p>",
"   <p>",
"    In many patients with postrabies vaccination and postmeasles ADEM, systemic blood lymphocyte sensitivity to MBP can be demonstrated in vitro, even though generalized cellular reactivity tends to be depressed in patients with systemic measles virus infection. Although technically difficult to assess, CSF lymphocyte sensitivity to MBP may be even more marked than is systemic lymphocyte sensitivity. The occurrence of cases without MBP sensitivity indicates that this assay is insufficiently sensitive to establish or exclude the diagnosis of ADEM.",
"   </p>",
"   <p>",
"    The diagnosis of ADEM can usually be made with confidence in the setting of a clear-cut antecedent event strongly associated with the disorder, such as measles infection or vaccination. The occurrence of an acute focal or multifocal central nervous system syndrome subsequent to a more nonspecific viral illness or vaccination in which the epidemiological link with ADEM is weak creates a wider differential diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial episode of what will prove to be MS &mdash; The presence of increased CSF IgG levels may favor MS. Follow-up MRI may be needed to distinguish the two disorders, since the initial MRI scans can appear similar [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/93\">",
"       93",
"      </a>",
"      ]. The occurrence of a nonspecific viral illness prior to the onset of the clinical neurologic syndrome does not distinguish between MS and ADEM, since the incidence of exacerbations of MS is increased following such infections.",
"     </li>",
"     <li>",
"      central nervous system vasculitis with or without systemic features (such as disseminated intravascular coagulation or serum sickness)",
"     </li>",
"     <li>",
"      Multiple cerebral infarcts, particularly embolic from infected cardiac valves",
"     </li>",
"     <li>",
"      Chronic meningitis or granulomatous disease (sarcoidosis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, encephalitis, abscess, or tumor needs to be excluded if the main clinical feature is unifocal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Acute hemorrhagic leukoencephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute hemorrhagic leukoencephalitis is a rare entity that represents a hyperacute form of ADEM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/94\">",
"     94",
"    </a>",
"    ]. The most frequent antecedent history is that of an upper respiratory infection. Given the nonspecific nature of the antecedent event and the lack of a specific diagnostic clinical laboratory test, the exact incidence and full clinical spectrum of the disorder can only be estimated and is based largely on descriptions of autopsy-proved cases.",
"   </p>",
"   <p>",
"    The clinical manifestations, including focal or multifocal signs, seizures, and obtundation, mimic ADEM but develop more abruptly and are more severe. Relapse following initial recovery has been described. Fever is common.",
"   </p>",
"   <p>",
"    The cerebrospinal fluid (CSF) usually demonstrates increased pressure, protein, and both white and red cells. The peripheral white blood cell count also is usually increased.",
"   </p>",
"   <p>",
"    CT scans in suspected clinical cases show an initially normal scan followed by low-density white matter lesions developing within 72 hours of the first symptoms. With improvement, the lesions on CT may largely resolve. MRI may yield additional information on lesion evolution.",
"   </p>",
"   <p>",
"    The differential diagnosis of this syndrome includes entities that present as rapidly evolving focal cerebral disorders with fever and obtundation. Examples are brain abscess and encephalitis, due particularly to herpes simplex, and those syndromes considered in the section on ADEM (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Acute disseminated encephalomyelitis'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Acute and subacute transverse myelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute and subacute transverse myelitis is defined as the development of isolated spinal cord dysfunction over hours or days in patients in whom there is no evidence of a compressive lesion. In the combined experience of several series reviewing complete transverse myelitis, 37 percent of patients reported a preceding febrile illness. The initial symptoms are paresthesias, back pain, or leg weakness; 37 percent of patients had the maximal deficit within one day, 45 percent in 1 to 10 days, and 18 percent in more than 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients presenting with acute complete transverse myelitis have a cited risk of MS of only 5 to 10 percent. However, partial or incomplete myelitis is a much more common clinical entity and bears more relevance to MS; 57 to 72 percent of patients with acute partial myelitis as an initial presentation have cranial MRI abnormalities consistent with MS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/16,96\">",
"     16,96",
"    </a>",
"    ]. Over three to five years, 60 to 90 percent of these patients developed MS, while 10 to 30 percent of those with a normal MRI developed MS. Cerebrospinal fluid (CSF) studies suggest that patients with monosymptomatic disease and positive oligoclonal bands (OCBs) have a higher risk of evolution to MS than those without OCBs, although CSF results do not help further in prognosis when compared with MRI alone. CSF analysis is most useful in the situation where MRI is not available. CSF analysis is helpful at excluding other inflammatory and infectious cause of transverse myelitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=see_link&amp;anchor=H3#H3\">",
"     \"Disorders affecting the spinal cord\", section on 'Transverse myelitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cerebellitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute, isolated ataxia has been observed after many different viral illnesses, but most frequently in association with varicella infections. Cerebellar ataxia accounts for 50 percent of the postvaricella neurologic syndromes, which overall occur in 1 in 1000 cases of childhood varicella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis for recovery is excellent, although the duration of symptoms varies from a few days up to three to four weeks. The fact that most cases remit spontaneously and the etiology (direct invasion versus autoimmune) is unresolved leaves the issue of glucocorticoid therapy unsettled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Neuromyelitis optica and optic-spinal MS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromyelitis optica (NMO, also called Devic disease) is characterized by a combination of bilateral optic neuropathy and cervical myelopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/98\">",
"     98",
"    </a>",
"    ]. NMO is more common in non Caucasian ethnic groups in North America than in Caucasians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/99\">",
"     99",
"    </a>",
"    ]. NMO may be the same disease as an Asian optic-spinal form of MS that accounts for 15 to 40 percent of MS cases in Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/98,100,101\">",
"     98,100,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NMO can be monophasic, but 73 to 90 percent of cases have a relapsing course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/98,102\">",
"     98,102",
"    </a>",
"    ]. In some patients the optic neuropathy and the myelopathy occur at the same time; in others, one or the other component is delayed. A minority of patients with NMO present with intractable vomiting as the initial symptom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the optic nerve and cervical spinal cord are common sites of lesions in MS. Thus, distinguishing NMO from MS may be difficult, particularly in patients with relapsing NMO, which accounts for most NMO cases. In addition, demyelination of the optic nerve and spinal cord can occur as a manifestation of acute disseminated encephalomyelitis or rarely of other autoimmune disease such as systemic lupus erythematosus.",
"   </p>",
"   <p>",
"    Several features appear to distinguish NMO from classical relapsing-remitting MS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The myelopathy with NMO tends to be more severe, with less likelihood of recovery.",
"     </li>",
"     <li>",
"      Brain MRI is often normal in patients with NMO, particularly at onset, and spinal cord MRI typically exhibits extensive lesions spanning three or more vertebral segments. However, retrospective data suggest that clinical or MRI evidence of brain involvement, particularly in the brainstem, occurs in a substantial proportion of patients with NMO [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/104-106\">",
"       104-106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During acute attacks of NMO, the cerebrospinal fluid (CSF) may exhibit a neutrophilic pleocytosis, but it is usually (70 to 85 percent of cases) negative for oligoclonal bands. On the other hand, elevated numbers of anti-myelin oligodendrocyte glycoprotein (MOG) secreting cells in the CSF have been observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/107\">",
"       107",
"      </a>",
"      ], supporting a humoral inflammatory mechanism in the pathogenesis of NMO.",
"     </li>",
"     <li>",
"      The neuropathologic features of NMO at autopsy are those of a much more severe necrotic lesion of the cord rather than incomplete demyelination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A serum IgG autoantibody (NMO-IgG) may be a specific marker for NMO. The NMO-IgG antibodies bind selectively to the aquaporin 4 water channel, a plasma membrane protein that is expressed in astrocytic foot processes at the blood-brain barrier [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/109\">",
"       109",
"      </a>",
"      ]. A case-control study reported that NMO-IgG had good sensitivity and specificity for the detection of neuromyelitis optica (73 and 91 percent, respectively) as well as for Asian optic-spinal MS (58 and 100 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/110\">",
"       110",
"      </a>",
"      ]. The diagnostic utility of NMO-IgG positivity was supported by a subsequent study from an independent group of investigators [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/111\">",
"       111",
"      </a>",
"      ], but requires further confirmation.",
"     </li>",
"     <li>",
"      During acute attacks, levels of glial fibrillary acidic protein (GFAP) in the CSF of patients with NMO and aquaporin (NMO-IgG) antibody seropositivity were significantly higher than levels of GFAP in the CSF of patients with MS during relapses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/112\">",
"       112",
"      </a>",
"      ]. This finding supports the hypothesis that the inflammatory processes in NMO primarily target astrocytes. The area postrema appears to be a preferential target of NMO-IgG antibodies that bind to astrocyte aquaporin 4 water channels, leading to astrocyte dysfunction and the clinical manifestations of nausea and vomiting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/113\">",
"       113",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Revised diagnostic criteria for NMO published in 2006 require optic neuritis, myelitis, and at least two of three supportive criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/114\">",
"     114",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A contiguous spinal cord lesion on MRI extending three or more segments",
"     </li>",
"     <li>",
"      Initial brain MRI not meeting usual diagnostic criteria for MS",
"     </li>",
"     <li>",
"      Seropositivity for NMO-IgG",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The revised criteria permit central nervous system involvement beyond the optic nerves and spinal cord as compatible with NMO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/114\">",
"     114",
"    </a>",
"    ]. These criteria should be considered preliminary until independently validated. In patients with recurrent optic neuritis, retrospective evidence suggests that NMO-IgG seropositivity is associated with an increased risk of poor visual outcome, transverse myelitis, and fulfillment of diagnostic criteria for NMO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no controlled trials evaluating the treatment of NMO. For acute attacks and relapses of myelitis and optic neuritis, many experts recommend intravenous glucocorticoids followed soon by plasmapheresis for refractory or progressive symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. For prevention of attacks, systemic immunosuppression with agents including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/118\">",
"     118",
"    </a>",
"    ] is used, given the evidence that humoral autoimmunity plays a role in the pathogenesis of NMO. Immunosuppression is usually continued for at least five years for patients who are NMO-IgG seropositive, including those presenting with a single attack, because they are at high risk for relapse or conversion to NMO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/116\">",
"     116",
"    </a>",
"    ]. Limited observational evidence suggests that interferon beta treatment is not effective and may be harmful when used to treat patients with NMO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/119,120\">",
"     119,120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H583036513\">",
"    <span class=\"h2\">",
"     Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) is a type of encephalomyelitis that predominantly involves the pons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/121\">",
"     121",
"    </a>",
"    ]. The clinical features include a relapsing-remitting pattern of diplopia, gait ataxia, dysarthria, and facial paresthesia along with characteristic radiologic appearance of punctate, curvilinear gadolinium-enhancing lesions on MRI scattered throughout the pons with variable involvement of the medulla, brachium pontis, cerebellum, midbrain, and spinal cord (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85858 \" href=\"mobipreview.htm?8/41/8856\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/19/35130/abstract/121-123\">",
"     121-123",
"    </a>",
"    ]. Neuropathology of the brainstem and cerebellar lesions demonstrates a predominantly T cell lymphocytic infiltrate in the perivascular white matter. Some patients have oligoclonal bands in the cerebrospinal fluid. The disorder is responsive to long-term glucocorticoid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359621\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple sclerosis (MS) is a clinical diagnosis. There are no clinical findings that are unique to this disorder, but some are highly characteristic (",
"      <a class=\"graphic graphic_table graphicRef63940 \" href=\"mobipreview.htm?21/53/22363\">",
"       table 1",
"      </a>",
"      ). Common symptoms of MS are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef61789 \" href=\"mobipreview.htm?33/55/34684\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MRI is the test of choice to support the clinical diagnosis of MS. The McDonald diagnostic criteria include specific clinical and MRI findings needed for the demonstration of lesion dissemination in time and space, the core requirement of the diagnosis (see",
"      <a class=\"local\" href=\"#H3\">",
"       'McDonald criteria'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      <strong>",
"       Dissemination in space",
"      </strong>",
"      is demonstrated on MRI by one or more T2 lesions in at least two of four MS-typical regions of the CNS (periventricular, juxtacortical, infratentorial, or spinal cord)",
"      <strong>",
"       or",
"      </strong>",
"      by the development of a further clinical attack implicating a different central nervous system site. For patients with brainstem or spinal cord syndromes, symptomatic MRI lesions are excluded from the criteria and do not contribute to lesion count. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'McDonald criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Dissemination in time",
"      </strong>",
"      is demonstrated on MRI by the simultaneous presence of asymptomatic gadolinium-enhancing and nonenhancing lesions at any time, or a new T2",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of its timing with reference to a baseline scan,",
"      <strong>",
"       or",
"      </strong>",
"      by the development of a second clinical attack. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'McDonald criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The amount of additional data needed to confirm the diagnosis of MS in patients with acute attacks varies with the clinical presentation (see",
"      <a class=\"local\" href=\"#H3\">",
"       'McDonald criteria'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with two or more attacks who have objective clinical evidence of two or more lesions or objective clinical evidence of one lesion with reasonable historical evidence of a prior attack, no additional data are required",
"     </li>",
"     <li>",
"      For patients with two or more attacks who have objective clinical evidence of one lesion, the criteria require evidence of",
"      <strong>",
"       dissemination in space",
"      </strong>",
"     </li>",
"     <li>",
"      For patients with one attack who have objective clinical evidence of two or more lesions, the criteria require evidence of",
"      <strong>",
"       dissemination in time",
"      </strong>",
"     </li>",
"     <li>",
"      For patients with one attack who have objective clinical evidence of one lesion (ie, a clinically isolated syndrome), the criteria require evidence of",
"      <strong>",
"       dissemination in space and time",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who present with insidious neurological progression suggestive of primary progressive MS, the criteria require evidence of the one year of disease progression plus two of the three following criteria (note that symptomatic MRI lesions are excluded from the criteria and do not contribute to lesion count for patients with brainstem or spinal cord syndromes) (see",
"      <a class=\"local\" href=\"#H3\">",
"       'McDonald criteria'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dissemination in space",
"      <strong>",
"       in the brain",
"      </strong>",
"      based upon one or more T2 lesions in at least two of four MS-typical regions of the central nervous system (periventricular, juxtacortical, infratentorial, or spinal cord)",
"     </li>",
"     <li>",
"      Dissemination in space",
"      <strong>",
"       in the spinal cord",
"      </strong>",
"      based upon two or more T2 lesions in the cord",
"     </li>",
"     <li>",
"      Positive cerebrospinal fluid findings with isoelectric focusing evidence of oligoclonal bands",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elevated IgG index",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Qualitative assessment of cerebrospinal fluid (CSF) for oligoclonal IgG bands (OCBs) using isoelectric focusing is the most important diagnostic CSF study when determining a diagnosis of MS. Elevation of the CSF immunoglobulin level relative to other protein components is a common finding in patients with MS. A positive CSF is based upon the finding of either OCBs different from any such bands in serum, or by an increased IgG index. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cerebrospinal fluid analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several inflammatory demyelinating disorders bear an unknown relationship to MS. A syndrome of slowly progressive spinal cord dysfunction can present a major diagnostic challenge. An acute tumor-like MS variant has been described in which some patients with demyelinating disease present with large (&gt;2 cm) acute lesions, often associated with edema or ring enhancement. (See",
"      <a class=\"local\" href=\"#H359983\">",
"       'Unusual clinical presentations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of MS is limited in the setting of a young adult who has had two or more clinically distinct episodes of central nervous system dysfunction with at least partial resolution. Diagnostic difficulties arise in patients who have atypical presentations, monophasic episodes, or progressive illness (",
"      <a class=\"graphic graphic_table graphicRef76753 \" href=\"mobipreview.htm?22/46/23276\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/1\">",
"      Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/2\">",
"      McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/3\">",
"      Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\". Ann Neurol 2005; 58:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/4\">",
"      Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/5\">",
"      Swanton JK, Rovira A, Tintore M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 2007; 6:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/6\">",
"      Rovira A, Swanton J, Tintor&eacute; M, et al. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol 2009; 66:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/7\">",
"      Montalban X, Tintor&eacute; M, Swanton J, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010; 74:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/8\">",
"      Filippi M, Rocca MA. MR imaging of multiple sclerosis. Radiology 2011; 259:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/9\">",
"      Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/10\">",
"      DeLuca GC, Williams K, Evangelou N, et al. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 2006; 129:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/11\">",
"      Newcombe J, Hawkins CP, Henderson CL, et al. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain 1991; 114 ( Pt 2):1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/12\">",
"      Offenbacher H, Fazekas F, Schmidt R, et al. Assessment of MRI criteria for a diagnosis of MS. Neurology 1993; 43:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/13\">",
"      Sch&auml;ffler N, K&ouml;pke S, Winkler L, et al. Accuracy of diagnostic tests in multiple sclerosis--a systematic review. Acta Neurol Scand 2011; 124:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/14\">",
"      Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/15\">",
"      Lee KH, Hashimoto SA, Hooge JP, et al. Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1991; 41:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/16\">",
"      Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993; 116 ( Pt 1):135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/17\">",
"      Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993; 43:2632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/18\">",
"      Bot JC, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004; 62:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/19\">",
"      Brex PA, O'Riordan JI, Miszkiel KA, et al. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 1999; 53:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/20\">",
"      Dalton CM, Brex PA, Miszkiel KA, et al. New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol 2003; 53:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/21\">",
"      Tortorella C, Codella M, Rocca MA, et al. Disease activity in multiple sclerosis studied by weekly triple-dose magnetic resonance imaging. J Neurol 1999; 246:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/22\">",
"      Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993; 33:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/23\">",
"      Simon JH. From enhancing lesions to brain atrophy in relapsing MS. J Neuroimmunol 1999; 98:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/24\">",
"      Molyneux PD, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998; 43:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/25\">",
"      Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999; 353:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/26\">",
"      Molyneux PD, Tofts PS, Fletcher A, et al. Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: a comparison of two computer assisted techniques. J Neurol Neurosurg Psychiatry 1998; 65:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/27\">",
"      Filippi M, Rovaris M, Capra R, et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain 1998; 121 ( Pt 10):2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/28\">",
"      Filippi M. Enhanced magnetic resonance imaging in multiple sclerosis. Mult Scler 2000; 6:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/29\">",
"      Wolansky LJ, Bardini JA, Cook SD, et al. Triple-dose versus single-dose gadoteridol in multiple sclerosis patients. J Neuroimaging 1994; 4:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/30\">",
"      Silver NC, Good CD, Barker GJ, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 1997; 120 ( Pt 7):1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/31\">",
"      Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988; 111 ( Pt 4):927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/32\">",
"      Morgen K, Jeffries NO, Stone R, et al. Ring-enchancement in multiple sclerosis: marker of disease severity. Mult Scler 2001; 7:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/33\">",
"      He J, Grossman RI, Ge Y, Mannon LJ. Enhancing patterns in multiple sclerosis: evolution and persistence. AJNR Am J Neuroradiol 2001; 22:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/34\">",
"      Rovira A, Alonso J, Cucurella G, et al. Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images. AJNR Am J Neuroradiol 1999; 20:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/35\">",
"      Guttmann CR, Ahn SS, Hsu L, et al. The evolution of multiple sclerosis lesions on serial MR. AJNR Am J Neuroradiol 1995; 16:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/36\">",
"      Petrella JR, Grossman RI, McGowan JC, et al. Multiple sclerosis lesions: relationship between MR enhancement pattern and magnetization transfer effect. AJNR Am J Neuroradiol 1996; 17:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/37\">",
"      Roychowdhury S, Maldjian JA, Grossman RI. Multiple sclerosis: comparison of trace apparent diffusion coefficients with MR enhancement pattern of lesions. AJNR Am J Neuroradiol 2000; 21:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/38\">",
"      Leist TP, Gobbini MI, Frank JA, McFarland HF. Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol 2001; 58:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/39\">",
"      van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998; 19:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/40\">",
"      van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998; 50:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/41\">",
"      Paolillo A, Pozzilli C, Gasperini C, et al. Brain atrophy in relapsing-remitting multiple sclerosis: relationship with 'black holes', disease duration and clinical disability. J Neurol Sci 2000; 174:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/42\">",
"      Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/43\">",
"      Simon JH, Lull J, Jacobs LD, et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 2000; 55:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/44\">",
"      Bitsch A, Kuhlmann T, Stadelmann C, et al. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol 2001; 49:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/45\">",
"      Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 2003; 60:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/46\">",
"      Gasperini C, Pozzilli C, Bastianello S, et al. Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images. J Neurol Neurosurg Psychiatry 1999; 67:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/47\">",
"      Barkhof F, van Waesberghe JH, Filippi M, et al. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain 2001; 124:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/48\">",
"      Brex PA, Molyneux PD, Smiddy P, et al. The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 2001; 57:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/49\">",
"      Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into \"black holes\". Neurology 2001; 57:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/50\">",
"      Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 2003; 126:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/51\">",
"      Bagnato F, Gupta S, Richert ND, et al. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch Neurol 2005; 62:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/52\">",
"      Naismith RT, Cross AH. Multiple sclerosis and black holes: connecting the pixels. Arch Neurol 2005; 62:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/53\">",
"      Poloni G, Minagar A, Haacke EM, Zivadinov R. Recent developments in imaging of multiple sclerosis. Neurologist 2011; 17:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/54\">",
"      Arnold DL, Riess GT, Matthews PM, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994; 36:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/55\">",
"      Rigotti DJ, Inglese M, Kirov II, et al. Two-year serial whole-brain N-acetyl-L-aspartate in patients with relapsing-remitting multiple sclerosis. Neurology 2012; 78:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/56\">",
"      Rigotti DJ, Inglese M, Gonen O. Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. AJNR Am J Neuroradiol 2007; 28:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/57\">",
"      Guo AC, MacFall JR, Provenzale JM. Multiple sclerosis: diffusion tensor MR imaging for evaluation of normal-appearing white matter. Radiology 2002; 222:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/58\">",
"      Oh J, Henry RG, Genain C, et al. Mechanisms of normal appearing corpus callosum injury related to pericallosal T1 lesions in multiple sclerosis using directional diffusion tensor and 1H MRS imaging. J Neurol Neurosurg Psychiatry 2004; 75:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/59\">",
"      Rovaris M, Gass A, Bammer R, et al. Diffusion MRI in multiple sclerosis. Neurology 2005; 65:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/60\">",
"      Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004; 56:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/61\">",
"      Beaulieu C, Allen PS. Determinants of anisotropic water diffusion in nerves. Magn Reson Med 1994; 31:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/62\">",
"      Kealey SM, Kim Y, Provenzale JM. Redefinition of multiple sclerosis plaque size using diffusion tensor MRI. AJR Am J Roentgenol 2004; 183:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/63\">",
"      Calabrese M, Battaglini M, Giorgio A, et al. Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis. Neurology 2010; 75:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/64\">",
"      Lassmann H. Cortical lesions in multiple sclerosis: inflammation versus neurodegeneration. Brain 2012; 135:2904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/65\">",
"      Popescu BF, Lucchinetti CF. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol 2012; 12:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/66\">",
"      Geurts JJ, Calabrese M, Fisher E, Rudick RA. Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012; 11:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/67\">",
"      Geurts JJ, Pouwels PJ, Uitdehaag BM, et al. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 2005; 236:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/68\">",
"      Geurts JJ, Roosendaal SD, Calabrese M, et al. Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology 2011; 76:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/69\">",
"      Calabrese M, Rinaldi F, Seppi D, et al. Cortical diffusion-tensor imaging abnormalities in multiple sclerosis: a 3-year longitudinal study. Radiology 2011; 261:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/70\">",
"      Seewann A, Kooi EJ, Roosendaal SD, et al. Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology 2012; 78:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/71\">",
"      Nelson F, Poonawalla AH, Hou P, et al. Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am J Neuroradiol 2007; 28:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/72\">",
"      Sethi V, Yousry TA, Muhlert N, et al. Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI. J Neurol Neurosurg Psychiatry 2012; 83:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/73\">",
"      McLean BN, Luxton RW, Thompson EJ. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain 1990; 113 ( Pt 5):1269.",
"     </a>",
"    </li>",
"    <li>",
"     Rudick RA, Whitaker JN. Cerebrospinal fluid tests for multiple sclerosis. In: Neurology/Neurosurgery Update Series, Scheinberg P (Ed), CPEC, Princeton, NJ 1987. Vol 7, p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/75\">",
"      Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005; 62:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/76\">",
"      Avasarala JR, Cross AH, Trotter JL. Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch Neurol 2001; 58:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/77\">",
"      Gronseth GS, Ashman EJ. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/78\">",
"      Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/79\">",
"      Gaertner S, de Graaf KL, Greve B, Weissert R. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology 2004; 63:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/80\">",
"      Lim ET, Berger T, Reindl M, et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005; 11:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/81\">",
"      Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007; 356:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/82\">",
"      Pelayo R, Tintor&eacute; M, Montalban X, et al. Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med 2007; 356:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/83\">",
"      Lampasona V, Franciotta D, Furlan R, et al. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 2004; 62:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/84\">",
"      Reder AT, Oger JJ. Anti-myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. Neurology 2004; 62:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/85\">",
"      Mattson DH, Roos RP, Arnason BG. Isoelectric focusing of IgG eluted from multiple sclerosis and subacute sclerosing panencephalitis brains. Nature 1980; 287:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/86\">",
"      Schmalstieg WF, Keegan BM, Weinshenker BG. Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion. Neurology 2012; 78:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/87\">",
"      Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol 1993; 33:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/88\">",
"      Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008; 131:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/89\">",
"      Akman-Demir G, Serdaroglu P, Tas&ccedil;i B. Clinical patterns of neurological involvement in Beh&ccedil;et's disease: evaluation of 200 patients. The Neuro-Beh&ccedil;et Study Group. Brain 1999; 122 ( Pt 11):2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/90\">",
"      Carmosino MJ, Brousseau KM, Arciniegas DB, Corboy JR. Initial evaluations for multiple sclerosis in a university multiple sclerosis center: outcomes and role of magnetic resonance imaging in referral. Arch Neurol 2005; 62:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/91\">",
"      Johnson RT, Griffin DE, Hirsch RL, et al. Measles encephalomyelitis--clinical and immunologic studies. N Engl J Med 1984; 310:137.",
"     </a>",
"    </li>",
"    <li>",
"     Olek MJ, Dawson, DM. Multiple Sclerosis and Other Inflammatory Demyelinating Diseases of the Central Nervous System. Butterworth-Heinemann, 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/93\">",
"      Kesselring J, Miller DH, Robb SA, et al. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain 1990; 113 ( Pt 2):291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/94\">",
"      Lieberman AP, Grossman RI, Lavi E. Case of the month: April 1997--a 32 year old man with mental status changes and a severe occipital headache. Brain Pathol 1998; 8:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/95\">",
"      Knebusch M, Strassburg HM, Reiners K. Acute transverse myelitis in childhood: nine cases and review of the literature. Dev Med Child Neurol 1998; 40:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/96\">",
"      Ford B, Tampieri D, Francis G. Long-term follow-up of acute partial transverse myelopathy. Neurology 1992; 42:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/97\">",
"      de Fraiture DM, Sie TH, Boezeman EH, Haanen HC. Cerebellitis as an uncommon complication of infectious mononucleosis. Neth J Med 1997; 51:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/98\">",
"      Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/99\">",
"      Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/100\">",
"      Misu T, Fujihara K, Nakashima I, et al. Pure optic-spinal form of multiple sclerosis in Japan. Brain 2002; 125:2460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/101\">",
"      Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003; 2:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/102\">",
"      Collongues N, Marignier R, Z&eacute;phir H, et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 2010; 74:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/103\">",
"      Apiwattanakul M, Popescu BF, Matiello M, et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol 2010; 68:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/104\">",
"      Chan KH, Tse CT, Chung CP, et al. Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol 2011; 68:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/105\">",
"      Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/106\">",
"      Cabrera-G&oacute;mez JA, Quevedo-Sotolongo L, Gonz&aacute;lez-Quevedo A, et al. Brain magnetic resonance imaging findings in relapsing neuromyelitis optica. Mult Scler 2007; 13:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/107\">",
"      Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 2004; 63:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/108\">",
"      Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993; 34:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/109\">",
"      Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/110\">",
"      Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/111\">",
"      Jarius S, Franciotta D, Bergamaschi R, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007; 68:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/112\">",
"      Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010; 75:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/113\">",
"      Popescu BF, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011; 76:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/114\">",
"      Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/115\">",
"      Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/116\">",
"      Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 2008; 10:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/117\">",
"      Carroll WM, Fujihara K. Neuromyelitis optica. Curr Treat Options Neurol 2010; 12:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/118\">",
"      Scott TF, Frohman EM, De Seze J, et al. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 77:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/119\">",
"      Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007; 13:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/120\">",
"      Shimizu J, Hatanaka Y, Hasegawa M, et al. IFN&beta;-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010; 75:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/121\">",
"      Pittock SJ, Debruyne J, Krecke KN, et al. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain 2010; 133:2626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/122\">",
"      Simon NG, Parratt JD, Barnett MH, et al. Expanding the clinical, radiological and neuropathological phenotype of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). J Neurol Neurosurg Psychiatry 2012; 83:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/19/35130/abstract/123\">",
"      Taieb G, Duflos C, Renard D, et al. Long-term outcomes of CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids) in a consecutive series of 12 patients. Arch Neurol 2012; 69:847.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1688 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35130=[""].join("\n");
var outline_f34_19_35130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H359621\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      McDonald criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Lesion characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Diagnostic utility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Spinal cord MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Active versus chronic lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Black holes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Advances in MRI techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cerebrospinal fluid analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Oligoclonal bands",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Expert recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Evoked potentials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinically isolated syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antimyelin antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H359983\">",
"      UNUSUAL CLINICAL PRESENTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359990\">",
"      Progressive spinal cord syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359997\">",
"      Tumefactive multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Acute disseminated encephalomyelitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Acute hemorrhagic leukoencephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Acute and subacute transverse myelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cerebellitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Neuromyelitis optica and optic-spinal MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H583036513\">",
"      Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H359621\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1688\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1688|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/38/39526\" title=\"diagnostic image 1\">",
"      42 yo MS brain MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/9/12439\" title=\"diagnostic image 2\">",
"      MRI Transverse myelitis and MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/44/15044\" title=\"diagnostic image 3\">",
"      38 yo MS brain MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/41/8856\" title=\"diagnostic image 4\">",
"      Brain MRI of CLIPPERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1688|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/53/22363\" title=\"table 1\">",
"      Clinical features of MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/55/34684\" title=\"table 2\">",
"      Presenting symptoms in MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/46/21227\" title=\"table 3\">",
"      Ancillary testing in MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/46/23276\" title=\"table 4\">",
"      Differential diagnosis of MS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22808?source=related_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/52/25416?source=related_link\">",
"      Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33673?source=related_link\">",
"      Adrenoleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/16/11530?source=related_link\">",
"      Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/10/17576?source=related_link\">",
"      Cerebrospinal fluid: Physiology and utility of an examination in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43192?source=related_link\">",
"      Clinical presentation and diagnosis of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37112?source=related_link\">",
"      Clinically isolated syndromes suggestive of multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36985?source=related_link\">",
"      Comorbid problems associated with multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16938?source=related_link\">",
"      Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40808?source=related_link\">",
"      Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/6/19561?source=related_link\">",
"      Lumbar puncture: Technique; indications; contraindications; and complications in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33978?source=related_link\">",
"      Neurologic manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/41/26265?source=related_link\">",
"      Treatment of progressive multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41082?source=related_link\">",
"      Treatment of relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_19_35131="Nonplat combinations NSCLC";
var content_f34_19_35131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonplatinum-based combination regimens for advanced NSCLC",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and schedule",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gemcitabine/Docetaxel",
"       </td>",
"       <td>",
"        <p>",
"         Gemcitabine 1000 mg/m2 days 1, 8",
"        </p>",
"        <p>",
"         Docetaxel 85 mg/m2 day 8",
"        </p>",
"       </td>",
"       <td>",
"        Every 3 weeks",
"       </td>",
"       <td>",
"        Ann Oncol 2005; 16:602",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gemcitabine/Paclitaxel",
"       </td>",
"       <td>",
"        <p>",
"         Gemcitabine 1000 mg/m2 days 1, 8",
"        </p>",
"        <p>",
"         Paclitaxel 200 mg/m2 day 1",
"        </p>",
"       </td>",
"       <td>",
"        Every 3 weeks",
"       </td>",
"       <td>",
"        J Clin Oncol 2002; 20:3578",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paclitaxel/Vinorelbine",
"       </td>",
"       <td>",
"        <p>",
"         Paclitaxel 135 mg/m2 day 1",
"        </p>",
"        <p>",
"         Vinorelbine 25 mg/m2 day 1",
"        </p>",
"       </td>",
"       <td>",
"        Every 2 weeks",
"       </td>",
"       <td>",
"        Ann Oncol 2004; 15:1048",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gemcitabine/Vinorelbine",
"       </td>",
"       <td>",
"        <p>",
"         Gemcitabine 1000 mg/m2 days 1, 8",
"        </p>",
"        <p>",
"         Vinorelbine 25 mg/m2 days 1, 8",
"        </p>",
"       </td>",
"       <td>",
"        Every 3 weeks",
"       </td>",
"       <td>",
"        J Clin Oncol 2004; 22:2348",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These are representative doses and schedules, which have varied in different trials.",
"    <div class=\"footnotes\">",
"     NSCLC: Non-small cell lung cancer.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35131=[""].join("\n");
var outline_f34_19_35131=null;
var title_f34_19_35132="Valve surgery nonischemic MR";
var content_f34_19_35132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Mitral valve surgery (repair or valve replacement) in patients with nonischemic mitral regurgitation (MR)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement mitral valve surgery is indicated in patients with MR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Symptomatic severe acute MR.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Severe symptomatic chronic MR (NYHA class II-IV) in the absence of severe left ventricular dysfunction (left ventricular ejection fraction [LVEF] less than 30 percent or end-systolic dimension greater than 55 mm).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Asymptomatic severe chronic MR with LVEF of 30 to 60 percent and/or end-systolic dimension &ge;40 mm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Among patients with severe chronic MR who require surgery, mitral valve repair is preferred to mitral valve replacement in the majority of patients and the patients should be referred to surgical centers experienced in mitral valve repair.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of mitral valve surgery in patients with MR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Mitral valve repair in experienced surgical centers in asymptomatic severe chronic MR with preserved left ventricular function (LVEF &gt;60 percent and end-systolic dimension less than 40 mm) if the estimated likelihood of successful repair without residual MR is greater than 90 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Asymptomatic patients with severe chronic MR and preserved left ventricular function who have new onset atrial fibrillation or pulmonary hypertension defined as a pulmonary artery systolic pressure &gt;50 mmHg at rest or &gt;60 mmHg with exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; If mitral valve repair is highly likely, severe chronic MR due to a primary abnormality in the mitral valve apparatus (ie, not functional MR), NYHA class III-IV symptoms, and severe left ventricular dysfunction (LVEF less than 30 percent or end-systolic dimension greater than 55 mm).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the usefulness of mitral valve surgery in patients with MR in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Mitral valve repair for severe MR due to severe left ventricular dysfunction (LVEF &lt;30 percent) in patients with persistent NYHA class III-IV symptoms despite optimal therapy for heart failure, including biventricular pacing if warranted.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that mitral valve surgery is not useful in patients with MR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Isolated mitral valve surgery for mild to moderate MR.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Asymptomatic patients with preserved left ventricular function (LVEF &gt;60 percent and end-systolic dimension less than 40 mm) if there is significant doubt about the feasibility of repair.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35132=[""].join("\n");
var outline_f34_19_35132=null;
var title_f34_19_35133="Nonrandomized trials novel targeted therapies NET";
var content_f34_19_35133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonrandomized trials of novel targeted therapies in neuroendocrine tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Molecular target(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patients*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tumor type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Objective tumor response rate, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median TTP or PFS",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        VEGF pathway inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bevacizumab",
"       </td>",
"       <td>",
"        VEGF",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        Carcinoid",
"       </td>",
"       <td>",
"        18",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        66 weeks",
"       </td>",
"       <td>",
"        Yao J; 2008",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Sunitinib",
"       </td>",
"       <td rowspan=\"2\">",
"        VEGFR-1, -2, -3; PDGFR-&alpha;, -&beta;; KIT; RET; CSF-1R; FLT3",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        Carcinoid",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        10.2 months (TTP)",
"       </td>",
"       <td rowspan=\"2\">",
"        Kulke M; 2008",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        Pancreatic NET",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        7.7 months (TTP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Sorafenib",
"       </td>",
"       <td rowspan=\"2\">",
"        VEGFR-2, PDGFR, FGFR-1, BRAF",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        Carcinoid",
"       </td>",
"       <td>",
"        7",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        7.8 months",
"       </td>",
"       <td rowspan=\"2\">",
"        Hobday T; 2007",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        Pancreatic NET",
"       </td>",
"       <td>",
"        11",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        11.9 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Pazopanib",
"       </td>",
"       <td rowspan=\"2\">",
"        VEGFR-1, -2, -3; PDGFR-&alpha;, -&beta;; KIT",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        Carcinoid",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        12.7 months",
"       </td>",
"       <td rowspan=\"2\">",
"        Phan AT; 2010",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        Pancreatic NET",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        11.7 months",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        mTOR inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Everolimus",
"       </td>",
"       <td>",
"        mTOR",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        Pancreatic NET",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        9.3 months",
"       </td>",
"       <td>",
"        Yao J; 2009",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Everolimus",
"       </td>",
"       <td rowspan=\"2\">",
"        mTOR",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Carcinoid",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        63 weeks",
"       </td>",
"       <td rowspan=\"2\">",
"        Yao J; 2010",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Pancreatic NET",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        50 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Everolimus",
"       </td>",
"       <td rowspan=\"2\">",
"        mTOR",
"       </td>",
"       <td>",
"        115",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Pancreatic NET",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        9.7 months",
"       </td>",
"       <td rowspan=\"2\">",
"        Yao J; 2010",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        Pancreatic NET",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        16.7 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Everolimus",
"       </td>",
"       <td>",
"        mTOR",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        Nonfunctioning pancreatic NET",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        17.1 months",
"       </td>",
"       <td>",
"        Oh DY; 2012",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Temsirolimus",
"       </td>",
"       <td rowspan=\"2\">",
"        mTOR",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        Carcinoid",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        6.0 months",
"       </td>",
"       <td rowspan=\"2\">",
"        Duran I; 2006",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        Pancreatic NET",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        10.6 months",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CSF-1R: colony-stimulating factor receptor; EGFR: epidermal growth factor receptor; KIT: stem cell factor receptor; mTOR: mammalian target of rapamycin; PDGFR: platelet-derived growth factor receptor; RET: rearranged during transfection or glial cell-line derived neurotrophic factor; VEGF: vascular endothelial growth factor; VEGFR: VEGF receptor; NET: neuroendocrine tumor; PFS: progression-free survival; TTP: time to tumor progression; NR: not reported.",
"     <br>",
"      * Number of patients evaluable for efficacy endpoints.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Patients also received treatment with octreotide.",
"       <br>",
"        &Delta; Confirmed.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         After failure of octreotide.",
"         <br>",
"          &sect; Concurrent with octreotide.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35133=[""].join("\n");
var outline_f34_19_35133=null;
var title_f34_19_35134="FEV1 and age in females";
var content_f34_19_35134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54935%7EPULM%2F66761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54935%7EPULM%2F66761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    FEV1 and age in healthy women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 308px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Growth and decline of lung function in healthy females. Actual values are shown in the top panel and growth velocity in the bottom panel.",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Sherrill DL, Camilli A, Lebowitz MD. Am Rev Respir Dis 1989; 140:638.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    FEV1 and age in healthy men",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 298px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Growth and decline of lung function in healthy males. Actual values are shown in the top panel and growth velocity in the bottom panel.",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Sherrill DL, Camilli A, Lebowitz MD. Am Rev Respir Dis 1989; 140:638.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35134=[""].join("\n");
var outline_f34_19_35134=null;
var title_f34_19_35135="Aural atresia";
var content_f34_19_35135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aural atresia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Failure of recanalization of the external auditory canal results in aural atresia. This child has aural atresia with a normal pinna.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_19_35135=[""].join("\n");
var outline_f34_19_35135=null;
 